



Literature Review

Artificial intelligence in medicine: What is it doing for us today? ☆

Aliza Becker*

The College of Professional Studies, The George Washington University, Alexandria, VA, United States



ARTICLE INFO

Article history:

Available online 29 March 2019

Keywords:

Artificial intelligence
Diagnosis
Machine learning
Patient care
Privacy
Treatment

ABSTRACT

With its origins in the mid- to late-1900s, today, artificial intelligence (AI) is used in a wide range of medical fields for varying purposes. This review first covers the early work regarding AI in medicine, then aims to elucidate some of the most current applications of machine learning in medicine according to the following four specific categories: (1) its use in assessing the risk of disease onset and in estimating treatment success; (2) its use in managing or alleviating complications; (3) its role in ongoing patient care; and (4) its use in ongoing pathology and treatment efficacy research. Lastly, this paper clarifies some of the potential drawbacks, concerns, and uncertainties surrounding the use of AI in medicine and briefly discusses some of the efforts being made to prepare the health care industry for the implementation of AI.

© 2019 Published by Elsevier Ltd on behalf of Fellowship of Postgraduate Medicine.

Early work

According to the history books, the earliest applications of artificial intelligence (AI) in the medical field occurred predominantly in the 1960s and 1970s (the term itself having been coined by John McCarthy in 1955 [1]). On a broader scale, early theorists like Alan Turing [2] first questioned whether or not computers could be made to operate in a manner similar to that of the human brain (i.e., “to think”). Application of early machine learning principles came with the introduction of the Polish “bomba” and British “bombe” machines used to decipher the Germans’ Enigma machine codes during World War II [3]. The development of the first AI program (i.e., the Logic Theory Machine) said to be capable of mimicking some aspects of humans’ problem-solving abilities is often attributed to Herbert Simon, Allen Newell, and John Shaw in the mid-1950s [4,5], though several researchers in the same decade also explored the possibility of developing chess- and checkers-playing programs [6–8], including Arthur Samuel, who is believed to have introduced the term “machine learning” [8]. Joseph Weizenbaum at the Massachusetts Institute of Technology held a similar role in early artificial intelligence application work with his ELIZA language processing program, which mimicked a human therapist by incorporating key words or phrases input by the user to produce a response [9].

With the eventual revelation that AI could perhaps be used to specifically solve or clarify complex biomedical problems, interest in its potential grew exponentially. In 1961, Warner et al. published a study on the use of an automated diagnostic system for diagnosing congenital heart disease, in which data were drawn from 1035 patients referred for cardiac catheterization and analyzed [10]. MYCIN, a computer program developed by researchers at Stanford University in the 1970s, was used to diagnose and recommend treatment—specifically antibiotics, with the dosage adjusted according to each individual patient’s body weight—for serious infections by identifying the bacteria in question causing the infection [11]. An earlier initiative conducted at the same institution, the Dendral project, had aimed to study hypothesis formation and discovery in science, specifically via assisting organic chemists in elucidating the structure of unknown organic molecules [12]. GUIDON, an intelligent computer-aided instruction program that uses AI techniques to represent both subject material and teaching strategies [13] was developed in the late 1970s for teaching infectious disease diagnosis to medical students through the use of case presentations. Other systems like INTERNIST-1 and its successor, Quick Medical Reference, were developed and put into play to assist health care professionals in patient diagnosis: these systems relied on a knowledge database of 570 diseases, which clinicians could reference when presented with a patient, while the latter system could also generate or refine hypotheses in complex cases [14]. Kulikowski and Weiss discussed the CASNET and EXPERT projects in the 1980s; the former was used in the context of glaucoma care, while the latter was established to help build models for reasoning in rheumatology and endocrinology [15]. As far back as 1959, an article in *Science* postulated how computers might fit into the process of patient diagnosis, acknowledging that

* **Submission declaration:** This work has not been published previously elsewhere and is not under consideration for publication elsewhere. Its publication is approved by all authors.

* Correspondence to: 322B Barton Run Blvd., Marlton, NJ 08053, United States.
E-mail address: arbecker1@gmail.com

“before computers can be used effectively ... we need to know more about how the physician makes a medical diagnosis,”[16] with subsequent research aiming to elucidate this process in the context of computer operation [17].

In later years, research turned towards evaluating computer-aided diagnosis in comparison with the abilities of human physicians. A controlled, prospective, unselected real-time comparison study involving 304 patients with abdominal pain conducted in the early 1970s found that the computing system’s overall diagnostic accuracy was higher than that of even the senior member of the clinical team [18]. A follow-up multicenter trial involving eight centers and more than 16,737 patients and 250 physicians, respectively, considered diagnostic accuracy using a baseline diagnosis method (human diagnosis) in comparison with computer-aided diagnosis; importantly, improvements in diagnosis, decision-making, and patient outcomes were noted with use of the latter [19]. Other research efforts attempted to utilize computers to generate new or more efficient methods of diagnosis not previously available through the compilation and use of standardized records, [20–23]; to improve the detection and classification of lesions in areas such as the vascular system, skin, lungs, or breasts via image analysis, [24–28]; and to elucidate biological mechanisms that may have previously been unknown [29,30]. Computer systems also began to find applicability in preventative medicine [31].

Today, AI is used in a wide range of medical fields for varying purposes. This review aims to discuss some of the most current applications of machine learning in medicine with respect to recent research published and products released, while also clarifying some of the potential drawbacks, concerns, and uncertainties surrounding its use. How the industry is preparing for the incorporation of this technology is also explored.

Current research

For the purposes of this section of the paper, which aims to act as a record of the various trends emerging in AI in medicine today, a PubMed literature search was conducted to identify relevant manuscripts published no earlier than 2015. Keywords included “artificial intelligence” AND “medicine” and “machine learning” AND “medicine.” Only original research studies, case reports, or reviews that drew new conclusions from the studies they surveyed with available abstracts and which had been published on the subject of AI in medicine were included. Papers published in languages other than English without an available English translation were excluded. Once trends were identified, a broader Internet search using the same keywords was conducted to identify any other relevant studies that may have been overlooked, though the findings from this search were limited.

From this literature survey, it became apparent that AI is being employed in the medical space in at least four distinct ways: (1) in the assessment of risk of disease onset and in estimating treatment success prior to initiation; (2) in an attempt to manage or alleviate complications; (3) to assist with patient care during the active treatment or procedure phase; and (4) in research aimed at elucidating the pathology or mechanism of and/or the ideal treatment for a disease. The following presents specific study examples of these four categories and discusses their significance.

In evaluating the risk of disease onset and potential treatment outcomes

The cardiovascular space represents one area of medicine in which AI has been largely influential. In a study published in *Medicine*, Li et al. developed an artificial neuron network (ANN)—a computational model constructed similarly in form to that of a biological neural network that “learns” based on information that

it is given—to predict the risk of congenital heart disease (CHD) in pregnant women, and found that the model was helpful in identifying those patients at high risk of developing CHD early on in pregnancy [32]. An ANN was also used in a multicenter comparison study evaluating whether the use of an ANN-based diagnostic system and conventional quantitation were comparable in diagnosing coronary artery disease [33]. Additionally, in a cohort of more than 370,000 patients free from cardiovascular disease, the use of machine learning was found to be beneficial in that it improved the accuracy of cardiovascular disease risk prediction through identifying patients who could benefit from preventative treatment, while also ruling out those in whom treatment would be unnecessary [34]. Jeganathan et al. evaluated the use of AI in mitral valve analysis, which is typically completed manually to diagnose patients with mitral valve disease. Their findings indicated that good reproducibility with minimal user intervention could be achieved via automated diagnosis [35]. Dawes et al. found that a machine learning model that uses three-dimensional cardiac motion was able to predict outcomes independently of conventional risk factors in patients with newly diagnosed pulmonary hypertension [36].

Machine learning has also been proven to be advantageous in assessing and identifying patients at risk for other diseases. One study by Kind et al. found that its use was beneficial in flagging individuals at high risk for colorectal cancer based on electronic medical records, including those with no visible clinical signs or symptoms [37]. Another employed machine learning to construct pretest models for predicting whether a patient would test positive for a particular respiratory virus [38]. Researchers at the Massachusetts Institute of Technology have developed a neural network model to identify depression from human speech patterns, regardless of what the speaker tells their physician [39]. Along this line, several papers also detail work being done to translate brainwaves into decipherable speech, which could eventually benefit those patients who are unable to talk [40]. Additionally, the use of AI in the diagnosis of melanoma [41], dementia [42], diabetic retinopathy [43], tuberculosis [44], and glaucoma [45] has also been investigated, as has its employment in predicting the outcome of radiation therapy [46], the occurrence of acute respiratory disease events and mortality in smokers [47], the success of substance abuse disorder treatment [48], the onset of diabetes [49,50], HIV transmission patterns [51], and the findings of breast cancer [52] and depression [53] in breast cancer patients, respectively. Assistance from AI to define certain subgroups within a patient population, such as individuals in the intensive care unit with similar clinical needs [54], or those patients with certain temporal bone abnormalities [55], has also been relied upon. Furthermore, while not representing an investigation on disease, per se, Stonko et al. were able to use an ANN to successfully predict trauma volume, the number of emergent operative cases, and average daily acuity at a level 1 trauma center by integrating temporal and weather data [56]. Ryyänen et al. considered the use of an AI method based on causal Bayesian networks to compare different treatment alternatives and identify patients who would benefit from treatment [57]. Though they evaluated the approach’s application in continuous positive airway pressure treatment of sleep apnea, they acknowledge that it may be applicable in other conditions as well [57]. Other researchers at IBM Research (Yorktown Heights, NY, USA) and Google (Mountain View, CA, USA) are focusing on the prediction of emergency room visit [58] and hospital outcome [59] trends using machine learning as well.

To alleviate or reduce complications

In addition to its uses prior to or at the time of disease onset, AI may also be useful in mitigating progression or further

adverse events of a disease. In a study by Dente et al., machine learning algorithms were used to identify predictive profiles of bacteremia and pneumonia in patients with combat wounds treated at the Walter Reed National Military Medical Center between 2007 and 2012 [60]. The researchers suggested that the implications of this study should also be considered in civilian trauma patients as well. Machine learning was also employed in the European Union-funded MOSAIC project to develop predictive models of type 2 diabetes mellitus complications such as retinopathy, neuropathy, and nephropathy using electronic medical records data [61]. Additionally, Wise et al. evaluated preoperative factors independently associated with prolonged postoperative ventilation in patients undergoing coronary artery bypass grafting, and aimed to optimize the identification of patients at risk before surgery using an ANN [62]. AI has also been used to estimate neurosurgical outcomes in focal epilepsy patients [63] and in predicting ischemic stroke and thromboembolism in patients with atrial fibrillation [64]. It may be beneficial in mitigating renal transplant rejection [65]. Furthermore, on the administration side, Hu et al. employed machine learning to better identify common complications in electronic health records data, as part of an effort to collect data for secondary purposes including research [66].

In ongoing patient care

With respect to its use during active treatment, AI predominantly appears to be beneficial in augmenting physicians' work. A study evaluating the use of computer-aided detection (CAD) of brain metastasis on radiologists' diagnostic performance in interpreting three-dimensional brain magnetic resonance imaging (MRI) scans found that CAD assistance helps radiologists to improve their diagnostic performance [67]. Researchers also employed AI to assess whether patients would tolerate major surgery or chemotherapy by analyzing their body morphometric age via muscle quantification [68], as well as in bone age assessment in the evaluation of patients with endocrine and metabolic disorders, respectively [69]. Other investigations indicate that AI may also have implications in intraoperative pathological diagnosis [70], the clinical management of patients undergoing echocardiographic evaluation [71], in collagen proportional area extraction during liver biopsy [72], in reducing the number of false-positive results when detecting nodules in chest radiographs [73], and in evaluating neurological deficit in stroke victims [74]. AI may also have some use in predicting long-term individualized disease progression [75], in evaluating childhood malnutrition [76], and in the analysis of breath samples to determine a patient's health status [77].

In clinical research and drug development

AI is also further expected help expedite clinical diagnosis and research. Researchers in Japan employed AI in the sequencing of cancer genomes to better identify patients with hematological malignancies and determine applicable drug information [78]. Additionally, a separate study by Heinson et al. on the use of machine learning indicated its applicability in distinguishing bacterial protective antigens (BPAs) from non-BPAs in reverse vaccinology, which could eventually assist in the development of new vaccines [79], while one by Romeo-Guitary et al. employed a systems biology approach and AI to identify a neuroprotective agent for the treatment of peripheral nerve root avulsion [80]. Researchers more recently published a proof-of-concept study on a computer system that can teach itself to design new drug molecules from scratch with certain desirable physical properties [81].

AI may also help to reveal new avenues for the diagnosis or monitoring of diseases that may ultimately simplify the task: in one study, Beck et al. used a machine-learning algorithm in the

prediction of breast cancer prognosis and identified stromal morphologic structure as a previously unrecognized prognostic determinant for breast cancer [82], while researchers in a separate study used retinal fundus images to predict cardiovascular risk factors they report were not previously thought to be present or quantifiable in retinal images, including age, gender, smoking status, and major adverse cardiac events [83]. Other applications of AI in the medical research setting include as part of a recent study aiming to generate accurate classification models using machine learning techniques that could be used to identify insulin-degrading enzyme modulators, which the researchers hope will lead to an effective treatment for Alzheimer's disease [84]. A study considering the use of machine learning in the development of membranolytic anticancer peptides reported that, of 12 sequenced, 10 were active against cancer cells [85]. Some researchers have also suggested that AI may be a solution to answering fundamental questions in the drug development pipeline, including who to recruit and what outcomes to measure in clinical drug trials [86], as well as the potential drug responses that could present [87,88]. Lastly, AI may change the manner in which animal testing as part of drug development and clinical trials is performed: in a study published in the journal *Toxicological Sciences*, the training of an AI interface to predict what the toxicity effects of thousands of unknown chemicals might be using data on the outcomes of previous animal tests showed an accuracy comparable to that obtained using live animal tests [89].

Concerns

Despite these applications, however, there are still a number of concerns surrounding the adoption of AI into medicine. First and foremost, ethical concerns have been voiced, in particular with respect to the use of artificial intelligence in the care of elderly patients [90]. It is largely understood that the AI movement in medicine is represented by two separate branches: the virtual and the physical [91]. The virtual branch is best characterized by the use of mathematical algorithms that induce learning through experience, while the physical branch encompasses most predominantly the use of robots. Though these robots are being used in the surgical setting to improve procedural outcomes [92–94], there is also a growing interest in their use in the care of elderly individuals. Here is where many of the ethical concerns surrounding the use of AI stem from. Sharkey et al. highlighted a number of such in their article, including (1) the potential for a reduction in the amount of human contact; (2) increased feelings of objectification and the loss of control as well as deception and infantilization in the elderly; and (3) a loss of privacy, personal liberty, and the existence of conflict regarding the circumstances in which elderly people should be allowed to control robots [95]. However, despite these thoughts, it has been suggested that, overall, the use of robot technology in elder care is beneficial [96], though more research on the subject is ultimately needed [97]. With respect to the former branch, there may be racial bias that could arise as a result of the data provided to the AI system: Char et al. [98] cite the example of the fact that data from the Framingham Heart Study used in nonwhite populations led to both the overestimation and underestimation of cardiovascular disease risk [99]. More broadly, Char et al. further stress that bias could possibly introduced into health data in three ways: via human bias; as bias that is introduced either by accident or on purpose (e.g., by the manufacturer) into the AI system's design; and as bias in the ways in which health care systems use the data (e.g., as a result of physicians' tendencies to possibly avoid patients with certain diagnoses, AI systems may designate these diagnoses as being always fatal and may adversely adjust treatment protocols in response) [98].

There is also lingering concern that AI might one day replace medical technicians or physicians, especially those in medical disciplines in which diagnosis is based on pattern recognition. Indeed, one recently published article asked radiologists, “are you working with AI or being replaced by AI?” [100] In an editorial published in the *Archives of Pathology & Laboratory Medicine*, Granter et al. hypothesize that, based on the recent success of Google’s (Menlo Park, CA, USA) AI computer program, AlphaGo, in beating the world’s best player of Go, a complex board game with ancient roots, that it is likely that AI may eventually replace the human microscopist [101]. A follow-up editorial by Sharma et al. refutes Granter et al.’s argument, but acknowledges that, in time, it is likely that human clinicians’ “cognitive lead” over AI will narrow [102]. Char et al. note that AI could represent a boon as clinical medicine moves progressively toward a shift-based model and the number of clinicians who see a patient from presentation to the end of treatment decreases, but may also gather unintended levels of power as the only consistent observer of the patient’s progression [98]. Other reports, however, while they have called to mention the potential threat of AI, have suggested that it will likely augment, rather than hurt, physicians’ work [103–105].

Even if AI does not replace physicians, reliance on its capabilities may lead to the deskilling of medical professionals, or to inadequate or incorrect computer-aided diagnosis. In a study by Anh et al., of 2298 electrocardiograms (ECGs) characterized as atrial fibrillation by a computer algorithm, 442 ECGs from 382 patients were deemed to represent incorrect diagnoses by two electrophysiologists who reviewed the scans [106]. Southern et al. detailed the presentation of a 62-year-old female who was mistakenly diagnosed via computer interpretation of her ECG with acute ischemia, and used the case report as the basis for a study evaluating the effects of incorrect computer diagnosis on medical resident decision-making [107]. Hakacova et al. found that automated systems were not on average significantly better than nonexpert physicians in diagnosing cardiac rhythm disorders based on ECG scans, and that automated systems can be incorrect in cases in which physicians are incorrect as well, leaving open the potential for misdiagnosing a patient [108]. Komorowski et al. also noted concern regarding the possibility of AI use resulting in the dissemination of too much patient data, leading diagnosis to become more complex than necessary [109].

Lastly, there are also concerns regarding the compilation of data associated with electronic medical records. Even as far back as 1960, patient data were being collected via electronic systems, and there were both advantages and disadvantages to such noted [110]; one paper from 1964 acknowledged “it appears that the most difficult and controversial subject is the handling of medical records,” due in part to the fact that no protocols were yet in place regarding what should be collected and how it should be maintained, despite the fact that collection of some sort was already ongoing [111]. With the increase in the complexity of computer systems, concern over patient data collection and storage as well as the efficacy of associated security measures has only grown [112,113]. As technology continues to advance and devices become more connected, patient privacy will become an increasingly larger, more worrying, and more complicated issue [131,114]. Also adding complexity is the idea that patient medical records represent a potential significant source of data to use in breakthrough research [115]; indeed, Char et al. suggest that data gathered about specific patients’ health, diagnostics, and outcomes will likely become part of large datasets and may be incorporated in future published literature or clinical trials without the patient’s consent or knowledge [98]. In such a situation, many have asked—who really owns the data? [116] In light of this, practitioners should perhaps strive to keep their patients as informed as possible regarding how their

medical records might be used and to obtain informed consent where they believe it might necessary.

Market offerings

At this time, there are a small but growing number of AI health care products on the market. Most current offerings appearing to be for use in patient diagnosis, and many seem specifically to supplement the abilities of existing imaging modalities. One example is the IDx-DR software program (IDx, LLC, Coralville, IA, USA) recently approved by the United States Food and Drug Administration (FDA), which uses an AI algorithm to analyze images of the eye taken with a retinal camera to spot symptoms of diabetic-related vision loss [117,118]. 20/20NOW similarly announced the release of its Eyelogic AI technology to assist in the diagnosis of retinal diseases [119]. Separately, the Viz.ai system (Viz.ai, Inc. Palo Alto, CA, USA), which connects to a hospital computed tomography scanner to alert the stroke specialist that a suspected large vessel occlusion stroke has occurred by relying on machine learning, was granted de novo classification by the FDA [120], while Imagen Technologies (New York, NY, USA) also obtained FDA approval to market its OsteoDetect computer-aided detection and diagnostic software, which employs an AI algorithm to analyze two-dimensional X-ray images for signs of distal radius fracture in adult patients [121]. Bay Labs (San Francisco, CA, USA) also recently received 510(k) clearance from the FDA for its EchoMD AutoEF software for the fully automated clip selection and calculation of left ventricular ejection fraction [122], with previous research having already demonstrated its good accuracy as compared with human cardiologists [123]. Butterfly Networks has received FDA clearance for the application of its Butterfly iQ® for iPhone AI-powered ultrasound imaging system in 13 clinical applications [124]. Subtle Medical has received both 510(k) clearance from the FDA and the European CE mark for its SubtlePET AI platform, which enhances the quality of images taken during positron emission tomography scans performed at a quicker pace [125], enabling an overall faster completion of patient imaging procedures. Similarly, HeartVista’s AI-driven, one-click autonomous MRI acquisition software can purportedly drastically cut the length of cardiac MRI scan procedures while simultaneously monitoring image quality [126]. Arterys, another manufacturer of an AI solution to supplement cardiac MRI, has added a number of enhancements to its original Cardio AI^{MR} platform [127]. Aidoc and MaxQ AI have additionally received FDA clearance for their respective AI technology offerings designed to assist with patient triage by flagging intracranial hemorrhage cases in head computed tomography scans [128,129]. Bayer and Merck have also jointly received a breakthrough device designation from the FDA for their chronic thromboembolic pulmonary hypertension AI pattern recognition software for use in conjunction with computed tomography pulmonary angiography [130]. QView Medical offers QVCAD, an FDA-approved AI system for concurrent reading of automated breast ultrasound scans [131].

Regarding other AI products that do not necessarily supplement the abilities of existing imaging systems, AliveCor has been busy in the realm of AI with the approval of their Kardia Pro AI-enabled monitoring platform for the early detection of atrial fibrillation [132] as well as the organization of a partnership with the Mayo Clinic for the development of tools for medical and non-medical personnel to easily screen for long QT syndrome through the combination of the company’s AI technology and the clinic’s patented algorithms [133]. A separate collaboration that yielded the KardiaK Platform, which screens for elevated levels of blood potassium without requiring any blood from the patient, has also received the FDA’s “Breakthrough Device” designation [134]. Another offering in the cardiology space that grew out of a collaboration between iRhythm Technologies and Stanford Medicine yielded

a AI-powered algorithm capable of diagnosing a variety of arrhythmias through single-lead electrocardiograms at a level similar to a human cardiologist; the algorithm recently received 510(k) clearance from the FDA [135].

Conversely, some AI applications support ongoing patient care after a diagnosis has been made. Beta Bionics, Inc. (Boston, MA, USA), a medical technology company working to incorporate AI into the world's first autonomous bionic pancreas, was previously granted investigational device exemption approval, allowing the company to move forward with the recruitment of both adults and children for home-use studies to test its iLet™ Bionic Pancreas System [136]. AliveCor has previously touted the release of medical research highlighting the potential use of the company's AI technology as a potential alternative to surgically implanted heart monitors, although this indication has not yet been FDA-approved [137]. VRHealth offers Luna, a virtual reality AI therapist trained with evidence-based psychological protocols that aims to reduce the physical and psychological effects of hot flashes in users [138]. Notal Vision is also moving forward with efforts to introduce an AI-enabled optical coherence tomography system for monitoring wet age-related macular degeneration at home in the elderly [139].

In some cases, manufacturers are focusing on how AI could support physicians directly. Amazon has launched its Comprehend Medical service, a HIPAA-eligible service that uses machine learning to identify patient diagnoses, symptoms, medical test findings, treatments, and other relevant medical data for easier review from “unstructured” medical text such as doctor's notes [140]. AiDoc and SaferMD have also announced a partnership aimed at improving the Medicare reimbursement of AI radiology procedures [141].

Reflection

Overall, while AI has come a long way since its infancy in terms of its incorporation into medicine, it still has a long way to go—and, it may never, in fact, reach a point at which it will be totally independent of a human physician. Considering whether AI is on par with physician assessment, a letter by van Smeden et al. [142] in response to a study evaluating the use of deep learning algorithms for the detection of lymph node metastases in women with breast cancer [143] cautioned that certain criteria must be standardized and employed to ensure fair comparison—something that, at this time, a human must develop and “feed” to the AI system.

Still, AI's possible uses in diagnosis, treatment, and clinical research remain numerous, and the industry on some levels is beginning to prepare for the inevitable through the establishment of working groups, guidelines, frameworks, and the like [144–147]. Only several months ago, for example, the American Medical Association passed its first policy guidelines on “augmented intelligence,” detailing five tasks that the organization will strive to perform [148]. In the image of the first workshops held in conjunction with the birth of modern AI [149], in more recent years, webinars, lecture series, and even entire conferences dedicated to the topic of AI in medicine have begun to spring up en masse [150–153]. Schools, too, on the subject of AI in health care are being established [154].

Furthermore, similar to how technology as a whole has become more readily adopted by younger individuals, AI's possible implications have begun to be considered more strongly in the education of the next generation of physicians [155]. One study by Uemura et al. suggested based on the findings of a study that employed an AI-based measure to analyze the hand movements of expert and novice surgeons that such could be used to provide feedback on surgeons' current skill levels and/or to inform them of areas in which they need to improve in [156]. Indeed, other research suggests that the majority of medical students agree that AI will im-

prove certain medical disciplines (i.e., radiology) and that there is a need to include AI in medical training [157].

Considering all of the above, more studies must be completed in a preparatory manner so as to further elucidate the potential of AI. Physicians must educate themselves on the advantages of this new technology as well as the pitfalls. Formal guidelines and regulations must be established with regard to not only determining the situations in which AI should or can be used or not but also with respect to the handling of patient data and company oversight; this is especially of importance in the wake of revelations from exposed internal company documents that IBM Corp.'s (Armonk, NY, USA) Watson supercomputer gave physicians inaccurate cancer treatment advice, with company medical specialists and customers reporting “multiple examples of unsafe and incorrect treatment recommendations” [158,159]. Thorough testing of AI systems in development [160] should also be completed against human clinicians so as to quantify and define the technology's abilities and limitations. The social, legal, and ethical implications of using AI in medicine must also be considered thoroughly [98,161]. The completion of these steps and others will ensure a smoother and more effective integration of AI into medicine.

Author statements

Funding

The author received no funding for this manuscript.

Competing interests

The author has no relevant conflicts of interest to disclose.

Ethical approval

Not required

References

- [1] Childs M. John McCarthy: Computer scientist known as the father of AI. <https://www.independent.co.uk/news/obituaries/john-mccarthy-computer-scientist-known-as-the-father-of-ai-6255307.html>. Accessed 15 June 2018.
- [2] Turing A. Computing Machinery and intelligence. *Mind* 1950;49:433–60.
- [3] Gladwin LA. Alan Turing, Enigma, and the breaking of German machine ciphers in World War II. Available at: Alan Turing, Enigma, and the breaking of German machine ciphers in World War II. Available at: <https://www.archives.gov/files/publications/prologue/1997/fall/turing.pdf>. Accessed 15 December 2018.
- [4] Newell A, Simon HA. Current developments in complex information processing. Technical report P-850. Santa Monica, CA: Rand Corporation.
- [5] Newell A, Shaw SC, Simon HA. Elements of a theory of human problem solving. *Psychol Rev* 1958;65(3):151–66.
- [6] Shannon CE. Programming a computer for playing chess. *Philos Mag* 1950;41(314):256–75.
- [7] Bernstein A, Roberts M de V. Computer v. chess-player. *Sci Am* 1958;198(6):96–107.
- [8] Samuel AL. Some studies in machine learning using the game of checkers. *IBM J* 1959;3(3):210–29.
- [9] Weizenbaum J. ELIZA—a computer program for the study of natural language communication between man and machine. *Commun ACM* 1966;9(1):36–45.
- [10] Warner HR, Toronto AF, Veasey LG, Stephenson R. A mathematical approach to medical diagnosis. Application to congenital heart disease. *JAMA* 1961;177:177–83.
- [11] Shortliffe EH. MYCIN: a knowledge-based computer program applied to infectious diseases. *Proc Annu Symp Comput Appl Med Care* 1977:66–9.
- [12] Lindsay RK, Buchanan BG, Feigenbaum EA, Lederberg J. Applications of artificial intelligence for organic chemistry. New York, NY: McGraw-Hill Book Company; 1980.
- [13] Clancey WJ, Shortliffe EH, Buchanan BG. Intelligent computer-aided instruction for medical diagnosis. *Proc Annu Symp Comput Appl Med Care* 1979;17:175–83.
- [14] Miller RA, McNeil MA, Challinor SM, Masarie FE Jr, Myers JD. The internist-1/quick medical reference project—status report. *West J Med* 1986;145(6):816–22.

- [15] Kulikowski CA, Weiss SM. Representation of expert knowledge for consultation: the CASNET and EXPERT Projects". Artificial intelligence in medicine. Szolovits P, editor. Boulder, CO: Westview Press; 1982.
- [16] Ledley RS, Lusted LB. Reasoning foundations of medical diagnosis; symbolic logic, probability, and value theory aid our understanding of how physicians reason. *Science* 1959;130(3366):9–21.
- [17] Szolovits P, Pauker SG. Categorical and probabilistic reasoning in medical diagnosis. *Artif Intell* 1978;11:115–44.
- [18] de Dombal FT, Leaper DJ, Staniland JR, McCann AP, Horrocks JC. Computer-aided diagnosis of acute abdominal pain. *Br Med J* 1972;2(5804):9–13.
- [19] Adams ID, Chan M, Clifford PC, et al. Computer aided diagnosis of acute abdominal pain: a multicentre study. *Br Med J (Clin Res Ed)* 1986;293(6550):800–4.
- [20] Farrar JT. Use of a digital computer in the analysis of intestinal motility records. *IRE Trans Med Electron* 1960;ME-7:259–63.
- [21] Heaf PJ. Automation in medicine. *Proc R Soc Med* 1964;57:1148–9.
- [22] Laska E, Morrill D, Kline NS, Hackett E, Simpson GM. SCRIBE-a method for producing automated narrative psychiatric case histories. *Am J Psychiatry* 1987;124(1):82–4.
- [23] Brodman K, van Woerkom AJ. Computer-aided diagnostic screening for 100 common diseases. *JAMA* 1966;197(11):901–5.
- [24] Fujita H, Doe K, Pencil LE, Chua KG. Image feature analysis and computer-aided diagnosis in digital radiography. 2. Computerized determination of vessel sizes in digital subtraction angiography. *Med Phys* 1987;14(4):549–56.
- [25] Giger ML, Doi K, MacMahon H. Computerized detection of lung nodules in digital chest radiographs. *Proc SPIE* 1987;767:384–6.
- [26] Giger ML, Doi K, MacMahon H. Image feature analysis and computer-aided diagnosis in digital radiography. 3. Automated detection of nodules in peripheral lung fields. *Med Phys* 1988;15:158–66.
- [27] Chan HP, Doi K, Galhotra S, Vyborny CJ, MacMahon H, Jokich PM. Image feature analysis and computer-aided diagnosis in digital radiography. 1. Automated detection of microcalcifications in mammography. *Med Phys* 1987;14:538–48.
- [28] Norins AL. Computers in dermatology. *Arch Dermatol* 1964;90:506–11.
- [29] Lewis FJ, Shimizu T, Schofield AL, Rosi PS. Analysis of respiration by an on-line digital computer system: clinical data following thoracoabdominal surgery. *Ann Surg* 1966;164(4):547–57.
- [30] Geivers H, Schaper W, Serves J, Xhonneux R. Cardiac excitability determined by electronic computer. *Pflügers Arch Gesamte Physiol Menschen Tiere* 1967;298(2):185–90.
- [31] Debray JR, Chrétien J, Gueniot M, et al. [A new concept of preventative medicine using automatic data processing by computer. II. Application to diseases and risks of the digestive apparatus and to cardiovascular diseases and risks]. *Ann Med Interne (Paris)* 1969;120(10):589–96.
- [32] Li H, Luo M, Zheng J, et al. An artificial neural network prediction model of congenital heart disease based on risk factors: a hospital-based case-control study. *Medicine (Baltimore)* 2017;96(6):e6090.
- [33] Nakajima K, Kudo T, Nakata T, et al. Diagnostic accuracy of an artificial neural network compared with statistical quantitation of myocardial perfusion images: a Japanese multicenter study. *Our J Nucl Med Mol Imaging* 2017 Sep 26 Epub ahead of print.
- [34] Weng SF, Repts J, Kai J, Garibaldi JM, Quereshi N. Can machine-learning improve cardiovascular risk prediction using routine clinical data. *PLoS One* 2017;12(4):e0174944.
- [35] Jeganathan J, Knio Z, Amador Y, et al. Artificial intelligence in mitral valve analysis. *Ann Card Anaesth* 2017;20(2):129–34.
- [36] Daws TJW, de Marvao A, Shi W, et al. Machine learning of three-dimensional right ventricular motion enables outcome prediction in pulmonary hypertension: a cardiac MR imaging study. *Radiology* 2017;283(2):381–90.
- [37] Kind Y, Akiva P, Choman E, et al. Performance analysis of a machine learning flagging system used to identify a group of individuals at a high risk for colorectal cancer. *PLoS One* 2017;12(2):e0171759.
- [38] Mai NV, Krauthammer M. Controlling testing volume for respiratory viruses using machine learning and text mining. *AMIA Annu Symp Proc* 2017;2016:1910–19.
- [39] Matheson R. Model can more naturally detect depression in conversations. Available at: <http://news.mit.edu/2018/neural-network-model-detect-depression-conversations-0830>. Accessed 15 January 2019.
- [40] Yirka B. Three studies show gains being made in using AI to create speech from brainwaves. Available at: <https://medicalxpress.com/news/2019-01-gains-ai-speech-brainwaves.html>. Accessed 15 January 2019.
- [41] Fuller C, Cellura AP, Hibler BP, Burtis K. Computer-aided diagnosis of melanoma. *Semin Cutan Med Surg* 2016;35(1):25–30.
- [42] Bhagyashree SIR, Nagaraj K, Prince M, Fall CHD, Krishna M. Diagnosis of dementia by machine learning methods in epidemiological studies: a pilot exploratory study from south India. *Soc Psychiatry Psychiatr Epidemiol* 2017 Jul 11 Epub ahead of print.
- [43] Gargeya R, Leng T. Automated identification of diabetic retinopathy using deep learning. *Ophthalmology* 2017;124(7):962–9.
- [44] Lakhani P, Sundaram B. Deep learning at chest radiography: automated classification of pulmonary tuberculosis by using convolutional neural networks. *Radiology* 2017;284(2):574–82.
- [45] Kim SJ, Cho KJ, Oh S. Development of machine learning models for diagnosis of glaucoma. *PLoS One* 2017;12(5):e0177726.
- [46] Kang J, Schwartz R, Flickinger J, Beriwal S. Machine learning approaches for predicting radiation therapy outcomes: a clinician's perspective. *Int J Radiat Oncol Biol Phys* 2015;93(5):1127–35.
- [47] González G, Ash SY, Vegas Sanchez-Ferrero G, et al. Disease staging and prognosis in smokers using deep learning in chest computed tomography. *Am J Respir Crit Care Med* 2017 Sep 11 Epub ahead of print.
- [48] Acion L, Kelmansky D, van der Laan M, Sahker E, Jones D, Arndt S. Use of a machine learning framework to predict substance use disorder treatment success. *PLoS One* 2017;12(4):e0175383.
- [49] Alghamdi M, Al-Mallah M, Keteyian S, Brawner C, Ehrman J, Sakr S. Predicting diabetes mellitus using SMOTE and ensemble machine learning approach: the Henry Ford Exercise Testing (FIT) project. *PLoS One* 2017;12(7):e0179805.
- [50] Olivera AR, Roesler V, Iochpe C, et al. Comparison of machine-learning algorithms to build a predictive model for detecting undiagnosed diabetes - ELSA-Brasil: accuracy study. *Sao Paulo Med J* 2017;135(3):234–46.
- [51] Young SD, You W, Wang W. Toward automating HIV identification: machine learning for rapid identification of HIV-related social media data. *J Acquir Immune Defic Syndr* 2017;74(2):S128–31 Suppl.
- [52] Zadeh Shirazi A, Seyyed Mahdavi Chabok SJ, Mohammadi Z. A novel and reliable computational intelligence system for breast cancer detection. *Med Biol Eng Comput* 2017 Sept 11 Epub ahead of print.
- [53] Cvetković J. Breast cancer patients' depression prediction by machine learning approach. *Cancer Invest* 2017;35(8):569–72.
- [54] Vranas KC, Jopling JK, Sweeney TE, et al. Identifying distinct subgroups of ICU patients: a machine learning approach. *Crit Care Med* 2017;45(10):1607–15.
- [55] Masino AJ, Grundmeier RW, Pennington JW, Germiller JA, Crenshaw EB 3rd. Temporal bone radiology report classification using open source machine learning and natural language processing libraries. *BMC Med Inform Decis Mak* 2016;16:65.
- [56] Stonko DP, Dennis BM, Betzold RD, Peetz AB, Gunter OL, Guillaumondegui OD. Artificial intelligence can predict daily trauma volume and average acuity. *J Trauma Acute Care Surg* 2018 Apr 19 Epub ahead of print.
- [57] Ryyänänen OP, Leppänen T, Kekolahti P, Mervala E, Töyräs J. Bayesian network model to evaluate the effectiveness of continuous positive airway pressure treatment of sleep apnea. *Health Inform Res* 2018 Oct;24(4):346–58.
- [58] Yong Q. Using deep learning to predict emergency room visits. Available at: <https://phys.org/news/2018-04-deep-emergency-room.html>. Accessed 11 July 2018.
- [59] Rajkumar A, Oren E, Chen K, et al. Scalable and accurate deep learning for electronic health records. *NPJ Digit Med* 2018;1:18.
- [60] Dentice CJ, Bradley M, School S, et al. Towards precision medicine: accurate predictive modeling of infectious complications in combat casualties. *J Trauma Acute Care Surg* 2017;83(4):609–16.
- [61] Dagliati A, Marini S, Sacchi L, et al. Machine learning methods to predict diabetes complications. *J Diabetes Sci Technol* 2017 May 1 Epub ahead of print.
- [62] Wise ES, Stonko DP, Glaser ZA, et al. Prediction of prolonged ventilation after coronary artery bypass grafting: data from an artificial neural network. *Heart Surg Forum* 2017;20(1):E007–14.
- [63] Sinha N, Dauwels J, Kaiser M, et al. Predicting neurosurgical outcomes in focal epilepsy patients using computational modelling. *Brain* 2017;140(2):319–32.
- [64] Li Z, Liu H, Du X, et al. Integrated machine learning approaches for predicting ischemic stroke and thromboembolism in atrial fibrillation. *AMIA Annu Symp Proc* 2017;2016:799–807.
- [65] Niel O, Bastard P. Artificial intelligence improves estimation of tacrolimus area under the concentration over time curve in renal transplant recipients. *Transpl Int* 2018 Apr 24 Epub ahead of print.
- [66] Hu Z, Melton GB, Moeller ND, et al. Accelerating chart review using automated methods on electronic health record data for postoperative complications. *AMIA Annu Symp Proc* 2017;2016:1822–31.
- [67] Sunwoo L, Kim YJ, Choi SH, et al. Computer-aided detection of brain metastasis on 3D MR imaging: observer performance study. *PLoS One* 2017;12(6):e0178265.
- [68] Lee H, Troschel FM, Tajmir S, Fuchs G, et al. Pixel-level deep segmentation: artificial intelligence quantifies muscle on computed tomography for body morphometric analysis. *J Digit Imaging* 2017;30(4):487–98.
- [69] Lee H, Tajmir S, Lee J, et al. Fully automated deep learning system for bone age assessment. *J Digit Imaging* 2017;30(4):427–41.
- [70] Zhang J, Song Y, Xia F, et al. Rapid and accurate intraoperative pathological diagnosis by artificial intelligence with deep learning technology. *Med Hypotheses* 2017;107:98–9.
- [71] Nath C, Albaghadi MS, Jonnalagadda SR. A natural language processing tool for large-scale data extraction from echocardiography reports. *PLoS One* 2016;11(4):e0153749.
- [72] Tsipouras MG, Giannakeas N, Tzallas AT, et al. A methodology for automated CPA extraction using liver biopsy image analysis and machine learning techniques. *Comput Methods Programs Biomed* 2017;140:61–8.
- [73] Suzuki K, Shiraishi J, Abe H, MacMahon H, Doi K. False-positive reduction in computer-aided diagnostic scheme for detecting nodules in chest radiographs by means of massive training artificial neural network. *Acad Radiol* 2005;12(2):191–201.
- [74] Park E, Chang HJ, Nam HS. Use of machine learning classifiers and sensor data to detect neurological deficit in stroke patients. *J Med Internet Res* 2017;19(4):e120.
- [75] Niel O, Boussard C, Bastard P. Artificial intelligence can predict GFR decline during the course of ADPKD. *Am J Kidney Dis* 2018;71(6):911–12.

- [76] Matchar E. Can AI tell if a child is malnourished?. Available at: <https://www.smithsonianmag.com/innovation/can-ai-tell-if-child-is-malnourished-180969268/>. Accessed 11 June 2018.
- [77] Soltoggio A. Artificial intelligence may be able to smell illnesses in human breath. Available at: <https://www.smithsonianmag.com/innovation/artificial-intelligence-may-be-able-to-smell-illnesses-in-human-breath-180969286/>. Accessed 11 June 2018.
- [78] Tojo A. Clinical sequencing in leukemia with the assistance of artificial intelligence. *Rinsho Ketsueki* 2017;58(10):1913–17.
- [79] Heinson AI, Gunawardana Y, Moesker B, et al. Enhancing the biological relevance of machine learning classifiers for reverse vaccinology. *Int J Mol Sci* 2017;18(2):pii: E312.
- [80] Romeo-Guitart D, Forés J, Herrando-Grabulosa M, et al. Neuroprotective drug for nerve trauma revealed using artificial intelligence. *Sci Rep* 2018;8(1):1879.
- [81] Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. *Sci Adv* 2018;4(7):eaap7885.
- [82] Beck AH, Sangoi AR, Leung S, et al. Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. *Sci Transl Med* 2011 Nov 9;3(108):108ra113.
- [83] Poplin R, Varadarajan AV, Blumer K, et al. Prediction of cardiovascular risk factors from retinal fundus photographs via deep learning. *Nat Biomed Eng* 2018;2:158–64.
- [84] Jamal S, Goyal S, Shanker A, Grover A. Machine learning and molecular dynamics based insights into mode of actions of insulin degrading enzyme modulators. *Comb Chem High Throughput Screen* 2017;20(4):279–91.
- [85] Grisoni F, Neuhaus C, Gabernet G, Müller A, Hiss J, Schneider G. Designing anticancer peptides by constructive machine learning. *ChemMedChem* 2018 Apr 21 Epub ahead of print.
- [86] Doyle OM, Mehta MA, Brammer MJ. The role of machine learning in neuroimaging for drug discovery and development. *Psychopharmacology (Berl)* 2015;232(21–22):4179–89.
- [87] Vidyasagar M. Identifying predictive features in drug response using machine learning: opportunities and challenges. *Annu Rev Pharmacol Toxicol* 2015;55:15–34.
- [88] Hall RG 2nd, Pasipanodya JG, Swancutt MA. Supervised machine-learning reveals that old and obese people achieve low dapson concentrations. *CPT Pharmacomet Syst Pharmacol* 2017;6(8):552–9.
- [89] Luechtefeld T, Marsh D, Rwolands C, Hartung T. Machine learning of toxicological big data enables read-across structure activity relationships (RASAR) outperforming animal test reproducibility. *Toxicol Sci* 2018 July 11 Epub ahead of print.
- [90] Ienca M, Wangmo T, Jotterand F, Kressig RW, Elger B. Ethical design of intelligent assistive technologies for dementia: a descriptive review. *Sci Eng Ethics* 2017 Sept 22 Epub ahead of print.
- [91] Hamet P, Tremblay J. Artificial intelligence in medicine. *Metabolism* 2017;69S:536–40.
- [92] Eichhorn KW, Westphal R, Rilk M, et al. Robot-assisted endoscope guidance versus manual endoscope guidance in functional endonasal sinus surgery (FESS). *Acta Otolaryngol* 2017;137(10):1090–5.
- [93] Sorokin I, Sundaram V, Singla N, et al. Robot-assisted versus open simple prostatectomy for benign prostatic hyperplasia in large glands: a propensity score-matched comparison of perioperative and short-term outcomes. *J Endourol* 2017 Sep 26 Epub ahead of print.
- [94] Xia L, Wang X, Xu T, Guzzo TJ. Systematic review and meta-analysis of comparative studies reporting perioperative outcomes of robot-assisted partial nephrectomy versus open partial nephrectomy. *J Endourol* 2017 Sep;31(9):893–909.
- [95] Sharkey A, Sharkey N. Granny and the robots: ethical issues in robot care for the elderly. *N Ethics Inf Technol* 2012;14(1):27–40.
- [96] Shishhegar M, Kerr D, Blake J. The effectiveness of various robotic technologies in assisting older adults. *Health Inform J* 2017 Sep 1 Epub ahead of print.
- [97] Coeckelbergh M. Care robots and the future of ICT-mediated elderly care: a response to doom scenarios. *AI Soc* 2016;31(4):455–62.
- [98] Char DS, Shah NH, Magnus D. Implementing machine learning in health care—addressing ethical challenges. *N Engl J Med* 2018;378(11):981–3.
- [99] Gijssberts CM, Groenewegen KA, Hofer IE, et al. Race/ethnic differences in the associations of the Framingham risk factors with carotid IMT and cardiovascular events. *PLoS One* 2015;10(7):e0132321.
- [100] Bluemke DA. Radiology in 2018: are you working with AI or being replaced by AI? *Radiology* 2018;287(2):365–6.
- [101] Granter SR, Beck AH, Jr Papke DJ. AlphaGo, deep learning, and the future of the human microscopist. *Arch Pathol Lab Med* 2017;141(5):619–21.
- [102] Sharma G, Carter A. Artificial intelligence and the pathologist: future frenemies. *Arch Pathol Lab Med* 2017;141(5):622–3.
- [103] Recht M, Bryan RN. Artificial intelligence: threat or boon to radiologists. *J Am Coll Radiol* 2017 Aug 19 Epub ahead of print.
- [104] O'Neill CO. Is AI a threat or benefit to health workers? *CMAJ* 2017;189(20):E732.
- [105] Cardiovascular Business. How deep learning is helping cardiologists—not threatening their jobs. Available at: <https://www.cardiovascularbusiness.com/topics/structural-heart/how-deep-learning-helping-cardiologists%E2%80%94not-threatening-their-jobs>. Accessed 11 July 2018.
- [106] Anh D, Krishnan S, Bogun F. Accuracy of electrocardiogram interpretation by cardiologists in the setting of incorrect computer analysis. *J Electrocardiol* 2006;39(3):343–5.
- [107] Southern WN, Arnsten JH. The effect of erroneous computer interpretation of ECGs on resident decision making. *Med Decis Making* 2009;29(3):372–6.
- [108] Hakacova N, Trägårdh-Johansson E, Wagner GS, Maynard C, Pahlm O. Computer-based rhythm diagnosis and its possible influence on nonexpert electrocardiogram readers. *J Electrocardiol* 2012;45(1):18–22.
- [109] Komorowski M, Celi LA. Will artificial intelligence contribute to overuse in healthcare. *Crit Care Med* 2017;45(5):912–13.
- [110] Beckett PG. Computers and clinical psychiatry. *IRE Trans Med Electron* 1960;ME-7:248–50.
- [111] Smith JC, Melton J. Manipulation of autopsy diagnosis by computer technique. *JAMA* 1964;188(11):958–62.
- [112] Petersen C. Through patients' eyes: regulation, technology, privacy, and the future. *Yearb Med Inform* 2018 Apr 22 Epub ahead of print.
- [113] Agaku IT, Adisa AO, Ayo-Yusuf OA, Connolly GN. Concern about security and privacy, and perceived control over collection and use of health information are related to withholding of health information from healthcare providers. *J Am Med Inform Assoc* 2014;21(2):374–8.
- [114] Papoutsis C, Reed JE, Marston C, Lewis R, Majeed A, Bell D. Patient and public views about the security and privacy of Electronic Health Records (EHRs) in the UK: results from a mixed methods study. *BMC Med Inform Decis Mak* 2015;15:86.
- [115] Coorevits P, Sundgren M, Klein GO, et al. Electronic health records: new opportunities for clinical research. *J Intern Med* 2013 Dec;274(6):547–60.
- [116] Morrissey J. The battle over patient data. How to secure your access. *Med Econ* 2014;91(20):16–18 20, 22–23.
- [117] IDx. FDA permits marketing of IDx-DR for automated detection of diabetic retinopathy in primary care. Available at: <https://www.eyediagnosis.net/single-post/2018/04/12/FDA-permits-marketing-of-IDx-DR-for-automated-detection-of-diabetic-retinopathy-in-primary-care>. Accessed 11 July 2018.
- [118] Abrámoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. *NPJ Digit Med* 2018;1:39.
- [119] PRNewswire. 20/20NOW implements retinal AI in all of its ocular telehealth exams. Available at: <https://www.prnewswire.com/news-releases/2020now-implements-retinal-ai-in-all-of-its-ocular-telehealth-exams-300730025.html>. Accessed 1 February 2019.
- [120] PR Newswire. Viz.ai granted de novo FDA clearance for first artificial intelligence triage software. <https://www.prnewswire.com/news-releases/vizai-granted-de-novo-fda-clearance-for-first-artificial-intelligence-triage-software-300599381.html>. Accessed 11 July 2018.
- [121] The United States Food and Drug Administration. FDA permits marketing of artificial intelligence algorithm for aiding providers in detecting wrist fractures. Available at: <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm608833.htm>. Accessed 11 July 2018.
- [122] Business Wire. Bay labs' echoMD autoEF software receives FDA clearance for fully automated AI echocardiogram analysis. Available at: <https://www.businesswire.com/news/home/20180619005552/en/Bay-Labs%E2%80%99-EchoMD-AutoEF-Software-Receives-FDA>. Accessed 11 July 2018.
- [123] Business Wire. New study demonstrates accuracy of fully-automated ejection fraction calculation using bay labs' echoMD autoEF software. <https://www.businesswire.com/news/home/20180625005217/en/New-Study-Demonstrates-Accuracy-Fully-Automated-Ejection-Fraction>. Accessed 11 July 2018.
- [124] Butterfly. A window into the human body for less than \$2,000 enabled by breakthrough Ultrasound-on-a-Chip technology. Available at: <https://www.butterflynetwork.com/press-releases/first-ultrasound-on-a-chip-receives-broadest-fda-510-k-clearance>. Accessed 15 January 2019.
- [125] PRNewswire. Subtle medical receives FDA 510(k) clearance and CE mark approval for SubtlePET™. Available at: <https://www.prnewswire.com/news-releases/subtle-medical-receives-fda-510k-clearance-and-ce-mark-approval-for-subtlepet-300760444.html>. Accessed 1 February 2019.
- [126] PRNewswire. HeartVista announces the first AI-driven, One Click™ Autonomous MRI solution to enable faster and more efficient scans that benefit patients, technicians, and radiologists. Available at: <https://www.prnewswire.com/news-releases/heartvista-announces-the-first-ai-driven-one-click-autonomous-mri-solution-to-enable-faster-and-more-efficient-scans-that-benefit-patients-technicians-and-radiologists-300754565.html>. Accessed 1 February 2019.
- [127] PRNewswire. Arterys introduces first complete AI- and Cloud-powered solution for most challenging medical imaging analysis workflow. Available at: <https://www.prnewswire.com/news-releases/arterys-introduces-first-complete-ai-and-cloud-powered-solution-for-most-challenging-medical-imaging-analysis-workflow-300735885.html>. Accessed 1 February 2019.
- [128] PRNewswire. A first in the world of radiology: aAidoc receives FDA clearance to enable radiologists to triage patients using AI. Available at: <https://www.prnewswire.com/news-releases/aaidoc-receives-fda-clearance-to-enable-radiologists-to-triage-patients-using-ai>. Accessed 1 February 2019.
- [129] PRNewswire. MaxQ AI receives FDA clearance for Accipio Ix™ intracranial hemorrhage platform. Available at: <https://www.prnewswire.com/news-releases/maxq-ai-receives-fda-clearance-for-accipio-ix-intracranial-hemorrhage-diagnostics-intelligence-platform-300745201.html>. Accessed 1 February 2019.

- [130] PRNewswire. FDA grants breakthrough device designation for CTEPH pattern recognition artificial intelligence software from Bayer and Merck. Available at: <https://www.prnewswire.com/news-releases/fda-grants-breakthrough-device-designation-for-cteph-pattern-recognition-artificial-intelligence-software-from-bayer-and-merck-300758747.html>. Accessed 1 February 2019.
- [131] PRNewswire. QVCAD, first AI system for concurrent reading of ABUS exams, featured in research and education sessions at RSNA. Available at: <https://www.prnewswire.com/news-releases/qvcad-first-ai-system-for-concurrent-reading-of-abus-exams-featured-in-research-and-education-sessions-at-rsna-300754370.html>. Accessed 1 February 2019.
- [132] AliveCor. AliveCor unveils first AI-enabled platform for doctors to improve stroke prevention through early atrial fibrillation detection. Available at: https://www.alivecor.com/press/press_release/alivecor-unveils-first-ai-enabled-platform-for-doctors/. Accessed 15 January 2019.
- [133] AliveCor. AI that sees the invisible: aAliveCor and Mayo Clinic announce collaboration to develop groundbreaking AI technology to help prevent sudden cardiac death. Available at: https://www.alivecor.com/press/press_release/ai-that-sees-the-invisible/. Accessed 15 January 2019.
- [134] AliveCor. FDA designates AliveCor's Bloodless hyperkalemia test a "breakthrough device." Available at: https://www.alivecor.com/press/press_release/fda-designates-alivecors-bloodless-hyperkalemia-test-a-breakthrough-device/. Accessed 15 January 2019.
- [135] Healio. AI system performs similarly to cardiologists to diagnose arrhythmias. Available at: <https://www.healio.com/cardiology/arrhythmia-disorders/news/online/%7B8c60c8cd-32e8-4ca5-b90e-7d9219a8585e%7D/ai-system-performs-similarly-to-cardiologists-to-diagnose-arrhythmias>. Accessed 15 January 2019.
- [136] Beta Bionics. Beta bionics receives IDE approval from the FDA to begin a home-use clinical trial testing the new iLetTM bionic pancreas system. Available at: https://docs.wixstatic.com/ugd/6df851_711995f7e8684c6fb2bec5d1e733c5fe.pdf. Accessed 11 July 2018.
- [137] PRNewswire. AliveCor AI found to compare favorably to surgically implanted loop recorder. Available at: <https://www.prnewswire.com/news-releases/alivecor-ai-found-to-compare-favorably-to-surgically-implanted-loop-recorder-300747731.html>. Accessed 15 January 2019.
- [138] PRNewswire. VRHealth announces new virtual reality AI-therapist that eases hot flashes. Available at: <https://www.prnewswire.com/news-releases/vrhealth-announces-new-virtual-reality-ai-therapist-that-eases-hot-flashes-300764227.html>. Accessed 1 February 2019.
- [139] PRNewswire. Notal Vision engages Wasatch Photonics, bringing AI-enabled home-based optical coherence tomography closer to market. Available at: <https://www.prnewswire.com/news-releases/notal-vision-engages-wasatch-photonics-bringing-ai-enabled-home-based-optical-coherence-tomography-closer-to-market-300767431.html>. Accessed 1 February 2019.
- [140] Kass-Hout TA, Wood M. Introducing medical language processing with Amazon Comprehend Medical. Available at: <https://aws.amazon.com/blogs/machine-learning/introducing-medical-language-processing-with-amazon-comprehend-medical/>. Accessed 15 January 2019.
- [141] PRNewswire. Aidoc and SaferMD team up to close the loop of AI radiology Medicare payments. Available at: <https://www.prnewswire.com/news-releases/aidoc-and-safermd-team-up-to-close-the-loop-of-ai-radiology-medicare-payments-809895876.html>. Accessed 1 February 2019.
- [142] van Smeden M, Van Calster B, Groenwold RHH. Machine learning compared with pathologist assessment. *JAMA* 2018;319(16):1725–6.
- [143] Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. *JAMA* 2017;318(22):2199–210.
- [144] Lin SY, Shanafelt TD, Asch SM. Reimagining clinical documentation with artificial intelligence. *Mayo Clin Proc* 2018;93(5):563–5.
- [145] Tang A, Tam R, Cadrin-Chênevert A, et al. Canadian Association of Radiologists white paper on artificial intelligence in radiology. *Can Assoc Radiol J* 2018;69(2):120–35.
- [146] Park SH, Kressel HY. Connecting technological innovation in artificial intelligence to real-world medical practice through rigorous clinical validation: what peer-reviewed medical journals could do. *J Kor Med Sci* 2018;33(22):e152.
- [147] United States Food and Drug Administration. Transforming FDA's approach to digital health. Available at: <https://www.fda.gov/NewsEvents/Speeches/ucm605697.htm>. Accessed 11 July 2018.
- [148] American Medical Association. AMA Passes First Policy Recommendations on Augmented Intelligence. Available at: <https://www.ama-assn.org/ama-passes-first-policy-recommendations-augmented-intelligence>. Accessed 29 August 2018.
- [149] Kulikowski CA. An opening chapter of the first generation of artificial intelligence in medicine: the first Rutgers AIM workshop, June 1975. *Yearb Med Inform* 2015;10(1):227–33.
- [150] AIME. 17th Conference on Artificial Intelligence in Medicine; 2019. Available at: <http://aime19.aimeinfo.org/>.
- [151] AIMed. What is AI Med? Available at: <https://ai-med.io/>. Accessed 1 February 2019.
- [152] AI World. AI in healthcare. Available at: <https://aiworld.com/Healthcare-AI>. Accessed 1 February 2019.
- [153] Ai4 Healthcare. What we do. Available at: <https://ai4.io/healthcare/>. Accessed 1 February 2019.
- [154] Derfel A. CHUM launches first French-language school of AI in medicine. Available at: <https://montrealgazette.com/news/local-news/chum-launches-first-french-language-school-of-ai-in-medicine>. Accessed 15 January 2019.
- [155] Claiborne JS. Anticipating and training the physician of the future: the importance of caring in an age of artificial intelligence. *Acad Med* 2018 Feb 13, <https://doi.org/10.1097/ACM.0000000000002175>, Epub ahead of print.
- [156] Uemura M, Tomikawa M, Miao T, et al. Feasibility of an AI-based measure of the hand motions of expert and novice surgeons. *Comput Math Methods Med* 2018;2018:9873273.
- [157] Pinto Dos Santos D, Giese D, Brodehl S, et al. Medical students' attitude towards artificial intelligence: a multicentre survey. *Eur Radiol* 2018 Jul 6 Epub ahead of print.
- [158] Ross C. IBM's Watson supercomputer recommended 'unsafe and incorrect' cancer treatments, internal documents show. Available at: <https://www.statnews.com/2018/07/25/ibm-watson-recommended-unsafe-incorrect-treatments/>. Accessed 29 August 2018.
- [159] Spitzer J. IBM's Watson recommended 'unsafe and incorrect' cancer treatments, STAT report finds. Available at: <https://www.beckershospitalreview.com/artificial-intelligence/ibm-s-watson-recommended-unsafe-and-incorrect-cancer-treatments-stat-report-finds.html>. Accessed 29 August 2018.
- [160] Forbes. This AI just beat human doctors on a clinical exam. Available at: <https://www.forbes.com/sites/parmyolson/2018/06/28/ai-doctors-exam-babylon-health/#5a8e93e12c0d>. Accessed 28 June 2018.
- [161] Lupton M. Some ethical and legal consequences of the application of artificial intelligence in the field of medicine. *Trends Med* 2018;18.

Vitamin K



by Aliza Becker, BA, MPS

Vitamin K is the generic name for a family of fat-soluble compounds that share a common 2-methyl-1,4-naphthoquinone ring structure. Vitamin K is naturally present in some foods or available as a dietary supplement.¹ Its existence was first reported in the 1930s by Danish biochemist Henrik Dam, who observed that chicks fed a low-fat diet free from sterols as part of research on cholesterol metabolism tended to develop subcutaneous and intramuscular hemorrhages;² subsequent research led to the discovery of an “anti-hemorrhagic factor” designated as vitamin K (with the “K” standing in for the German word *koagulationsvitamin*).³ Dam was later awarded the Nobel Prize in Physiology or Medicine in 1943, sharing with Edward Adelbert Doisy, an American biochemist, for

their discovery of vitamin K and its chemical structure, respectively.⁴

SOURCES AND DOSING

Two forms of vitamin K exist in the United States (US) food supply.¹ Vitamin K1 (phylloquinone [PK]) is found in green, leafy vegetables, such as collards, spinach, and broccoli, as well as in soybean oil and canola oil.⁵ In contrast, vitamin K2 (menaquinone [MK]) is found variably in certain animal-based foods and is mainly produced by bacteria and archaea. Notably, at least 15 types of MKs exist that are distinguishable by the number of isoprene units in their side chains. In a study of the US diet, Elder et al⁶ reported that chicken, cheddar cheese, and egg yolks contained the highest amounts of MK-4, while Fu et al,⁷ following a similar analysis of the US food supply, found that all processed pork products and fresh pork cuts contained MK-4, MK-10, and MK-11.

Vermeer et al⁸ reported that many cheeses contain MK-4 through MK-9, with levels depending on factors such as fat content, age, and country of origin. Meanwhile, among the vegetables they assessed, only the two fermented ones, natto and sauerkraut, contained MK8; the latter, a Japanese dish made from fermented soybeans, is considered a good source of MK-7.⁹ Certain gut bacteria, such as *Escherichia coli* (*E. coli*) and *Bacteroides* species, may also produce MK.¹⁰

According to US dietary guidelines, the recommended daily amount of vitamin K for adults over the age of 19 years is 90µg/day for women (including pregnant or breastfeeding women) and 120µg/day for men.¹¹ Children require anywhere from 2 to 75µg/day, depending on their age.¹¹

Although the U.S. population largely meets the recommended daily intake for vitamin K, certain populations are at risk for deficiency.

Newborns are typically given oral and/or intramuscular prophylactic vitamin K after birth to prevent hemorrhagic disease of the newborn,^{12,13} which can occur soon after birth due to the limited placental transfer of this vitamin during gestation and their sterile gut or later in infancy when coupled with insufficient vitamin K in breast milk.¹⁴ Although some research has previously suggested a link between intramuscular vitamin K and childhood leukemia,¹⁵ later reports have since argued against this connection.¹⁶ Individuals with disorders characterized by the malabsorption of fat, such as cystic fibrosis, chronic pancreatitis, and inflammatory bowel diseases, as well as those who have undergone certain surgical procedures, such as total pancreatectomy, small-bowel resections, or bariatric surgical procedures, may also benefit from vitamin K supplementation.¹⁷ Patients on hemodialysis may also present with a poor vitamin K status,¹⁸ and individuals taking drugs that interfere with vitamin K metabolism are similarly at risk of deficiency.¹⁹

EFFECTS IN THE BODY

For several decades after its discovery, vitamin K was thought to be used only for the synthesis of four blood-coagulation factors in the liver. In more recent years, however, researchers have expanded their

focus, elucidating possible roles of vitamin K in the transportation of calcium to bone and the reduction of vascular calcification via the carboxylation of osteocalcin and activation of matrix Gla protein, two vitamin K-dependent proteins (VKDPs), respectively.

Effects on bone health.

Sim et al²⁰ reported that increased dietary intake of PK-rich green leafy vegetables for four weeks in a population of middle-aged healthy men and women led to improved osteoblast function, which is thought to be due to vitamin K's role in increasing osteocalcin entry into the bone matrix and improving the material properties of bone (e.g., toughness). Moore et al²¹ found that the serum PK concentration was significantly lower in their study group of postmenopausal women with prior fractures compared to the no-fracture group and was independently associated with fracture risk. Cheung et al²² also suggested that daily PK supplementation may protect against fractures in postmenopausal women with osteopenia. Torbergsen et al²³ also observed that low serum concentrations of PK and 25-hydroxyvitamin D were significantly associated with risk of fracture in elderly patients hospitalized for hip fracture, implicating a synergistic effect between these two vitamins in addition to their independent roles.

Effects on cardiovascular health. Beulens et al²⁴ reported that high dietary MK intake, but probably not PK, may limit coronary calcification. Geleijnse et al²⁵ reported that MK intake was inversely related to all-cause mortality and severe aortic calcification, while PK intake did not correlate with any of their study outcomes. Vissers et al²⁶ noted that a high intake of MKs was associated with a reduced risk of peripheral arterial disease, at least in participants with hypertension, but a high intake of PK was not associated with the same. Gast et al²⁷ suggested that a high intake of MKs, especially MK-7, MK-8, and MK-9, could protect against coronary heart disease. However, PK may not be without its benefits: Shea et al²⁸ reported that PK supplementation slowed the progression of coronary artery calcification in healthy older adults with pre-existing coronary artery calcification. In patients with blood-clotting disorders, vitamin K antagonists (e.g., warfarin) are used to prevent stroke in patients with atrial fibrillation as well as venous thromboembolism, while PK itself is given to reduce the anticoagulant effects of such drugs.²⁹ Of note, vitamin K antagonists have been linked to higher levels of coronary artery and vascular calcification,^{30,31} but the coronary-calcification effect appears absent

with the use of newer non-vitamin K antagonist oral anticoagulants.³¹

Other effects on health.

Vitamin K may also lower the risk of type 2 diabetes mellitus,³² and research is ongoing concerning its potential in the treatment of cancer, particularly with regard to the effects of MKs on cell-cycle arrest and the inhibition of cell differentiation, apoptosis, autophagy, and invasion.³³ More generally, vitamin K may act as an anti-inflammatory³⁴ and an antioxidant,³⁵ and it has been associated with the inhibition of cognitive decline³⁶ and the prevention and treatment of neurodegenerative diseases, such as Alzheimer's.³⁷

Most recently, research has reported that levels of dephosphorylated-uncarboxylated matrix Gla protein, a marker of vitamin K deficiency,³⁸ was greater in patients with COVID-19 relative to healthy controls,³⁹ with higher levels present in those with more severe disease.⁴⁰

Editor's note: Vitamin K can lessen the effectiveness of Warfarin, a commonly prescribed blood thinner. Consult with your doctor to determine which vitamin K regimen is best for you.

SOURCES

1. Booth SL. Vitamin K: food composition and dietary intakes. *Food Nutr Res.* 2012;56.
2. Dam H. Cholesterol metabolism in hen eggs and chickens [in German]. *Niochem Z.*

QUICK GUIDE TO DIETARY SOURCES OF VITAMIN K

- Green leafy vegetables**
 - kale
 - spinach
 - turnip greens
 - collards
 - Swiss chard
 - mustard greens
 - parsley
 - romaine
 - green leaf lettuce
- Animal-based foods**
 - fish
 - liver
 - meat (chicken, pork)
 - eggs
 - cheese
- Grains**
 - fortified cereals
- Other vegetables**
 - Brussels sprouts
 - broccoli
 - cauliflower
 - cabbage

3. Dam H. The antihemorrhagic vitamin of the chick. *Biochem J.* 1935;29(6):1273-1285.
4. Raju TN. The Nobel chronicles. 1943: Henrik Carl Peter Dam (1895-1976); and Edward Adelbert Doisy (1893-1986). *Lancet.* 1999;353(9154):761.
5. Booth SL. Vitamin K: food composition and dietary intakes. *Food Nutr Res.* 2012;56:10.3402/fnr.v56i0.5505.
6. Elder SJ, Haytowitz DB, Howe J, et al. Vitamin k contents of meat, dairy, and fast food in the U.S. diet. *J Agric Food Chem.* 2006;54(2):463-467.
7. Fu X, Shen X, Finnan EG, et al. Measurement of multiple vitamin K forms in processed and fresh-cut pork products in the U.S. food supply. *J Agric Food Chem.* 2016;64(22):4531-4535.
8. Vermeer C, Raes J, van 't Hoofd C, et al. Menaquinone content of cheese. *Nutrients.* 2018;10(4):446.
9. Tsukamoto Y, Ichise H, Kakuda H, Yamaguchi M. Intake of fermented soybean (natto) increases circulating vitamin K2 (menaquinone-7) and gamma-carboxylated osteocalcin concentration in normal individuals. *J Bone Miner Metab.* 2000;18(4):216-222.
10. Ramotar K, Conly JM, Chubb H, Louie TJ. Production of menaquinones by intestinal anaerobes. *J Infect Dis.* 1984;150(2):213-218.
11. National Institutes of Health Office of Dietary Supplements. Vitamin K fact sheet for consumers. Available at: <https://ods.od.nih.gov/factsheets/VitaminK-Consumer/>. Accessed October 21, 2021.
12. American Academy of Pediatrics, Committee on Nutrition Vitamin K compounds and the water-soluble analogues: use in therapy and prophylaxis in pediatrics. *Pediatrics.* 1961;28:501-507.
13. American Academy of Pediatrics Committee on Fetus and Newborn. Controversies concerning vitamin K and the newborn. American Academy of Pediatrics Committee on Fetus and Newborn. *Pediatrics.* 2003;112(1 Pt 1):191-192.
14. Kher P, Verma RP. Hemorrhagic disease of newborn. [Updated 2021 Jul 3]. In: StatPearls

CREAMED WINTER GREENS

Servings: 6

Ingredients

- 1 15oz can chickpeas, rinsed and drained
- Cooking spray
- 2 tablespoons chopped almonds or pine nuts
- 1 to 2 tablespoons olive oil
- One small onion, minced (~3/4 cup)
- 1 to 2 cloves garlic, minced
- 1 large bunch fresh greens, such as collards, kale, and/or spinach
- 1/2 cup coconut milk
- 1/4 teaspoon nutmeg
- 1/4 teaspoon salt
- 1/8 teaspoon pepper
- 1 teaspoon tapioca or cornstarch, optional



Directions

1. Thoroughly rinse the greens under running tap water and dry in a salad spinner or with clean paper towels. Remove the stems and tear the leaves into small pieces (you should end up with ~6 to 7 cups of prepared greens).
2. Heat olive oil in a large pot over medium heat. Add the onion and sauté for about 5 minutes or until translucent. Add the garlic and sauté a minute or two.
3. Add the greens a handful at a time while you continue to stir them around until all have been added and they have wilted a bit. Then stir in the coconut milk, nutmeg, salt, and pepper, and cook for 3 to 4 minutes more, until hot.
4. To thicken the sauce, mix the tapioca or cornstarch with a small amount of cold tap water. Mix until lump free and then to the greens and cook until thickened.
5. Top with toasted chickpeas and almonds or pine nuts

Nutrition Facts (per serving)

Calories: 388; Total Fat (g): 14.9; Saturated Fat (g): 5.5; Cholesterol (mg): 0; Sodium (mg): 144; Total Carbohydrate (g): 51; Dietary Fiber (g): 14.3; Total Sugars (g): 9.3; Protein (g): 16.3; Calcium (mg): 150; Iron (mg): 6; Potassium (mg): 969 NHR

- [Internet]. Treasure Island, Florida: StatPearls Publishing; 2021.
15. Golding J, Greenwood R, Birmingham K, Mott M. Childhood cancer, intramuscular vitamin K, and pethidine given during labour. *BMJ*. 1992;305(6849):341-346.
 16. Fear NT, Roman E, Ansell P, et al. Vitamin K and childhood cancer: a report from the United Kingdom Childhood Cancer Study. *Br J Cancer*. 2003;89(7):1228-1231.
 17. Siener R, Maxhaka I, Alteheld B, et al. Effect of fat-soluble vitamins A, D, E and K on vitamin status and metabolic profile in patients with fat malabsorption with and without urolithiasis. *Nutrients*. 2020;12(10):3110.
 18. Cranenburg ECM, Schurgers LJ, Uiterwijk HH, et al. Vitamin K intake and status are low in hemodialysis patients. *Kidney Int*. 2012;82(5):605-610.
 19. Tufano A, Coppola A, Contaldi P, et al. Oral anticoagulant drugs and the risk of osteoporosis: new anticoagulants better than old? *Semin Thromb Hemost*. 2015;41(4):382-388.
 20. Sim M, Lewis JR, Prince RL, et al. The effects of vitamin K-rich green leafy vegetables on bone metabolism: a 4-week randomised controlled trial in middle-aged and older individuals. *Bone Rep*. 2020;12:100274.
 21. Moore AE, Kim E, Dulnoan D, et al. Serum vitamin K 1 (phyloquinone) is associated with fracture risk and hip strength in post-menopausal osteoporosis: a cross-sectional study. *Bone*. 2020;141:115630.
 22. Cheung AM, Tile L, Lee Y, et al. Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. *PLoS Med*. 2008;5(10):e196.
 23. Torbergsen AC, Watne LO, Wyller TB, et al. Vitamin K1 and 25(OH)D are independently and synergistically associated with a risk for hip fracture in an elderly population: a case control study. *Clin Nutr*. 2015;34(1):101-106.
 24. Beulens JWJ, Bots ML, Atsma F, et al. High dietary menaquinone intake is associated with reduced coronary calcification. *Atherosclerosis*.

- 2009;203(2):489–493.
25. Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. *J Nutr.* 2004;134(11):3100–3105.
 26. Vissers LET, Dalmeijer GW, Boer JMA, et al. The relationship between vitamin K and peripheral arterial disease. *Atherosclerosis.* 2016;252:15–20.
 27. Gast GCM, de Roos NM, Sluijs I, et al. A high menaquinone intake reduces the incidence of coronary heart disease. *Nutr Metab Cardiovasc Dis.* 2009;19(7):504–510.
 28. Shea MK, O'Donnell J, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women^{1,2,3,4}. *Am J Clin Nutr.* 2009;89(6):1799–1807.
 29. Zirikli A, Bode C. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. *J Thromb Thrombolysis.* 2017;43(3):365–379.
 30. Koos R, Mahnken AH, Mühlenbruch G, et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. *Am J Cardiol.* 2005;96(6):747–749.
 31. Weijts B, Blaauw Y, Rennenber JMW, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. *Eur Heart J.* 2011;32(20):2555–2562.
 32. Manna P, Kalita J, et al. Beneficial role of vitamin K supplementation on insulin sensitivity, glucose metabolism, and the reduced risk of type 2 diabetes: a review. *Nutrition.* 2016;32(7–8):732–739.
 33. Xv F, Chen J, Duan L, Li S. Research progress on the anticancer effects of vitamin K₂. *Oncol Lett.* 2018;15(6):8926–8934.
 34. Fujii S, Shimizu A, Takeda N, et al. Systematic synthesis and anti-inflammatory activity of ω-carboxylated menaquinone derivatives—investigations on identified and putative vitamin K metabolites. *Bioorg Med Chem.* 2015;23(10):2344–2352.
 35. Li J, Wang H, Rosenberg PA. Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes. *J Neurosci Res.* 2009;87(9):1997–2005.
 36. Alisi L, Cao R, De Angelis C, et al. The relationships between vitamin K and cognition: a review of current evidence. *Front Neurol.* 2019;10:239.
 37. Popescu A, German M. Vitamin K₂ holds promise for Alzheimer's prevention and treatment. *Nutrients.* 2021;13(7):2206.
 38. Dalmeijer GW, van der Schouw YT, Magdeleyns E, et al. The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein. *Atherosclerosis.* 2012;225(2):397–402.
 39. Desai AP, Dirajlal-Fargo S, Durieux JC. Vitamin K & D deficiencies are independently associated with COVID-19 disease severity. *Open Forum Infect Dis.* 2021;8(10):ofab408.
 40. Dofferhoff ASM, Piscaer I, Schurgers LJ, et al. Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19 [published online ahead of print August 27, 2020]. *Clin Infect Dis.*

NHR

About the Author



Ms. Becker is the managing editor of *The Journal of Innovations in Cardiac Rhythm Management*. She also works as a freelance editor and as a teaching assistant for the George Washington University's Master of Professional Studies in Publishing program.

VETERANS NEWS

Veterans Health Administration (VHA) increases care provided under MISSION Act

The 2018 Maintaining Internal Systems and Strengthening Integrated Outside Networks (MISSION) Act allows eligible vets to receive care from non-VHA healthcare providers. The program has vastly expanded in the last several years—33 million veteran community care appointments were completed in fiscal year 2021.

Access full story: <https://thehill.com/opinion/healthcare/582583-veterans-health-administration-increases-care-provided-under-mission-act>

Smoking rates steadily trend down among veterans receiving VA care

Cigarette use continues to decline nationwide, and the number of veterans enrolled in VA healthcare who identified as smokers has dropped nearly 20% in 21 years, from 33% in 1999 to 13.3% in 2020.

Access full story: <https://www.va.gov/opa/pressrel/pressrelease.cfm?id=5742>


Veterans exposed to burn pits will get expanded healthcare support, White House says

The Biden administration recently announced a series of new support options for veterans who have been exposed to “contaminants and environmental hazards,” such as burn pits, while serving.

Access full story: <https://www.cnn.com/2021/11/11/politics/military-exposure-burn-pits-biden-administration/index.html>

NHR

SUGAR and the Human Body



by Aliza Becker,
BA, MPS

Sugar, together with fruits, vegetables, fibers, and legumes, falls under the umbrella term of *carbohydrates*, which is one of the three macronutrients—alongside protein and fat—present in the human diet.¹ Sugar may be categorized in several different ways. First, there are simple sugars, known as monosaccharides, which are considered the most basic, fundamental units of a carbohydrate. Examples of simple sugars include glucose, galactose, and fructose.¹ In addition, there are compound sugars, called disaccharides, which

contain two monosaccharides. Examples of compound sugars include sucrose and lactose.¹

An oligosaccharide is any carbohydrate formed using 3 to 10 monosaccharide units, examples of which include raffinose and stachyose (found in legumes). A polysaccharide contains more than 10 monosaccharide units, and includes starches, glycogen, and fiber, such as pectin and cellulose.^{1,2} Monosaccharides and disaccharides are known as simple carbohydrates, whereas oligosaccharides and polysaccharides are considered complex carbohydrates.¹ All carbohydrates, including sugars, contain carbon,

hydrogen, and oxygen atoms in varying numbers arranged in different ways.¹

SUGAR IN THE BODY Healthy sugar processing in a healthy body.

Carbohydrate digestion begins in the mouth, where an enzyme in saliva, salivary amylase, breaks the bonds between the monomeric sugar units of more complex carbohydrates. Digestion of carbohydrates continues by mechanical means in the stomach; however, carbohydrate digestion is most extensive in the small intestine, where pancreatic amylase from the pancreas and enzymes secreted by intestinal cells that line the

villi initiate further breakdown of any remaining larger carbohydrate chains; the resulting monosaccharides are subsequently absorbed into the bloodstream and transported to the liver.^{1,3}

Upon the arrival of monosaccharides, the liver then works to convert galactose to glucose and to break fructose into smaller carbon-containing units, either storing glucose as glycogen or returning it back to the blood.³ In the latter case, the resultant increase in blood glucose prompts cells in the pancreas to secrete insulin, which triggers other cells throughout the body to transport glucose from the blood into different organ cells to use as fuel.^{1,3} As this process occurs and blood glucose levels are reduced, other pancreatic cells release glucagon, which signals the liver to break down stored glycogen and release it into the blood as glucose, thus ensuring that blood glucose levels remain within the target range.^{1,3}

Dysfunctional sugar processing in the body.

Lactose intolerance. In individuals with lactose intolerance, an inadequate amount of the enzyme lactase leads to subpar breakdown of lactose in the small intestine. This results in undigested lactose continuing to the large intestine, where bacteria digest it, generating gases that cause diarrhea, bloating, and abdominal cramps.³

Hypoglycemia and hyperglycemia. Hypoglycemia occurs when the blood glucose level is too low, often defined by a plasma glucose concentration of less than 70mg/dL,⁴ and is most commonly the result of medications taken to control diabetes, although other medications, critical illness or organ failure, a reaction to carbohydrates, an insulin-producing tumor in the pancreas, and some types of bariatric surgery can also trigger this state. In contrast, hyperglycemia may be diagnosed when the blood glucose is too high (i.e., greater than 125mg/dL while fasting or greater than 180mg/dL 2 hours after a meal). Hyperglycemia may result from damage to the pancreas, endocrine disorders that cause peripheral insulin resistance, the use of certain medications, total parental nutrition and dextrose infusion, or following surgery or trauma.⁶ Although hyperglycemia can be a symptom of diabetes, it does not necessarily warrant a diagnosis of diabetes when presenting alone.⁶

Prediabetes and diabetes. A diagnosis of prediabetes is typically based on the individual having a fasting (i.e., having nothing to eat or drink for at least 8 hours other than water) plasma glucose level of 100 to 125mg/dL, a hemoglobin A1c concentration (i.e., the amount of glucose attached to hemoglobin) of

5.7 to 6.4 percent, or a two-hour postload glucose level of 140 to 199mg/dL. A diagnosis of diabetes is typically based on having a fasting plasma glucose level of at least 126mg/dL, a two-hour plasma glucose level of at least 200mg/dL during a 75g oral glucose tolerance test, or a hemoglobin A1c concentration of 6.5 percent or higher.⁷

Three primary types of diabetes exist—namely, Type 1, Type 2, and gestational diabetes. Type 1 diabetes, also known as insulin-dependent diabetes, immune-mediated diabetes, or juvenile-onset diabetes (although it can occur at any age), results from cellular-mediated autoimmune destruction of β -cells in the pancreas, leading to limited or no secretion of insulin.⁸ Type 2 diabetes, also known as noninsulin-dependent diabetes or adult-onset diabetes, in contrast, occurs in individuals with insulin resistance or a relative (rather than absolute) insulin deficiency.⁸ Type 2 diabetes may be clearly differentiated from Type 1 diabetes by its lack of autoimmune destruction of β -cells in the latter.⁸ Given the autoimmune component, patients with Type 1 diabetes are also not generally overweight/obese, while those with or at risk for Type 2 diabetes typically are overweight or obese. Excess carbohydrate intake contributes both to weight gain and higher


SUGAR— NOT ALL THAT BAD?

Although sugar functions as a source of energy for the body, in special cases, it may also provide additional benefits.



- Sucrose and glucose have been shown to be effective analgesics in newborns undergoing heel-lancing, venipuncture, or intramuscular injection.¹
- Sugar may be useful in wound healing by promoting a low-moisture environment that inhibits bacterial growth.²
- Hossain et al³ suggested that the anti-hyperlipidemic effect of D-allulose, a no-calorie sweetener, in combination with its anti-inflammatory actions on adipocytes may be beneficial in the prevention of both obesity and atherosclerosis.
- Hayashi et al⁴ noted that D-allulose suppressed the postprandial blood glucose elevation primarily in borderline diabetes cases.
- Soterakis et al⁶ observed that the rate of alcohol removal from the blood was increased after ingesting fructose or sucrose compared to glucose.

SOURCES

1. Taddio A, Shah V, Hancock R, et al. Effectiveness of sucrose analgesia in newborns undergoing painful medical procedures. *CMAJ*. 2008;179(1):37-43.
3. Chirife J, Herszage L, Joseph A, Kohn ES. *In vitro* study of bacterial growth inhibition in concentrated sugar solutions: microbiological basis for the use of sugar in treating infected wounds. *Antimicrob Agents Chemother*. 1983;23(5):766-773.
4. Hossain A, Yamaguchi F, Matsuo T, et al. Rare sugar D-allulose: Potential role and therapeutic monitoring in maintaining obesity and type 2 diabetes mellitus. *Pharmacol Ther*. 2015;155:49-59.
5. Hayashi N, Iida T, Yamada T, et al. Study on the postprandial blood glucose suppression effect of D-psicose in borderline diabetes and the safety of long-term ingestion by normal human subjects. Study on the postprandial blood glucose suppression effect of D-psicose in borderline diabetes and the safety of long-term ingestion by normal human subjects. *Biosci Biotechnol Biochem*. 2010;74(3):510-519.
6. Soterakis J, Iber FL. Increased rate of alcohol removal from blood with oral fructose and sucrose. *Am J Clin Nutr*. 1975;28(3):254-257. 

levels of sugar in the blood, and obesity increases the amounts of substances involved in the development of insulin resistance.⁹ Gestational diabetes, on the other hand, occurs or is first identified during pregnancy,⁸ although the International Association of Diabetes and Pregnancy Study Groups recommended in 2009 that high-risk women found to have diabetes at their initial prenatal visit should receive a diagnosis of overt (i.e., pre-pregnancy) diabetes rather than gestational diabetes.¹⁰ Women at higher risk for developing gestational diabetes during pregnancy include those with marked obesity, a personal history of gestational diabetes, glycosuria (too much sugar in the urine), or a strong family history of diabetes.⁸ As a general rule, therefore, diabetes can be either a result of dysfunction in the body's ability to process sugar or due to taking in more sugar than the body can properly process.

It has been recommended by the American Association of Clinical Endocrinologists and American College of Endocrinology that all adults aged 45 years and older be screened for prediabetes and diabetes regardless of their perceived risk,¹¹ while the United States Preventative Service Task Force (USPSTF) has suggested screening individuals with overweight or obesity who are 40 to 70 years of age.¹² According to

the USPSTF, asymptomatic pregnant individuals should be screened for gestational diabetes no earlier than 24 weeks of pregnancy.¹³

HEALTH EFFECTS OF SUGAR CONSUMPTION

Natural vs. refined. Sugars as a group may be divided into two main types: natural and processed (or refined) sugars. While some sugar, such as glucose, fructose, and lactose, can be found in plants, fruits, and milk, others (e.g., high-fructose corn syrup) are created by way of heavy processing of certain natural sources such as sugar cane, sugar beets, and corn and are known as processed or refined sugars.¹⁴ Certain sugars, such as sucrose, may also be defined as natural or processed depending on their source.¹⁴

Although natural and processed sugars are essentially metabolized in the body the same way, different effects can be observed among the different types of sugars.¹⁵ Natural sugars are typically consumed in more limited quantities along with other nutrients, such as fiber and protein; as a result, natural sugars tend to be digested more slowly than added/refined sugars, ensuring the metabolism remains more stable over time.¹⁵ In contrast, refined/processed sugars are typically added to foods in variable, sometimes significant, quantities,¹⁵

resulting in variable processes of breakdown and variable amounts released into the bloodstream.

In a study that compared of the effects of different amounts of glucose, sucrose, or fructose added to tea to differing portions of carbohydrates in white bread (containing sucrose) on plasma glucose and insulin responses, Lee et al¹⁶ found that the mean postconsumption glycemic and insulinemic index values of glucose were greater and those of fructose were smaller, respectively, in tea than those of the bread.

Evans et al¹⁷ reported following a systematic review and meta-analysis that substituting fructose for glucose or sucrose in food or beverages lowers both peak postprandial blood glucose and insulin concentrations.

Yunker et al¹⁸ concluded from their study that sucrose is less efficient at signaling postprandial satiation than glucose.

Finally, Teff et al¹⁹ contended that, because fructose does not stimulate insulin secretion as glucose does, meals high in fructose likely result in lower concentrations of the hormone leptin, which is regulated by insulin-mediated glucose metabolism and is responsible, along with insulin, for long-term regulation of energy balance. As such, chronic consumption of diets high in fructose could facilitate persistent reductions in both

insulin and leptin, leading to increased caloric intake and weight gain.

Cardiovascular disease (CVD). Persistently increased amounts of sugar intake, which can raise the blood sugar level, have been linked to a number of adverse health effects. Malik et al²⁰ reported that the consumption of sugar-sweetened beverages, collectively considered to be one of the most significant contributors to added sugar intake in the United States,²¹ was positively associated with CVD in a dose-response manner.

In a meta-analysis and systematic review of 5,301 articles, Yin et al²² narrowed the effect further, observing that a one serving-per-day increment of sugar-sweetened beverages was associated with an eight-percent higher risk of both CVD and mortality.

According to the results of a study by Kim et al,²³ a one serving-per-day increment of sugar-sweetened beverages was also associated with a similarly heightened risk of hypertension.

In a Swedish population-based prospective cohort study, Janzi et al²⁴ found that more than eight servings a week of sugar-sweetened beverages was associated with an increased risk (19%) of stroke.

Swaminathan et al²⁵ reported that systolic and diastolic blood pressure values were higher in study participants with a greater

intake of refined grains, which include fewer nutrients and may be processed more rapidly in the body, leading to a greater increase in postprandial blood glucose concentrations as a result of the refinement process. Along these lines, Musa-Veloso et al²⁶ also documented an association between the consumption of intact oat kernels and a significant reduction in postprandial blood glucose levels compared to the consumption of refined grain.

In a meta-analysis, Meng et al²⁷ reported that increased intake of both sugar-sweetened and artificially sweetened beverages was associated with increased risk of Type 2 diabetes, CVD, and all-cause mortality.

Kidney and liver disease.

The kidneys are also adversely affected by excess sugar in the blood. While the kidneys normally help to filter most glucose out from the blood for reabsorption, when the blood glucose level reaches at least 180mg/dL, such as in those individuals with uncontrolled diabetes, the kidneys begin excreting sugar into the urine in larger amounts ($\geq 25\text{mg/dL}$)—a condition known as glycosuria.²⁸ In patients with diabetes, diabetic nephropathy may emerge as a result of hyperglycemia,²⁹ leading to chronic kidney disease and end-stage renal failure.³⁰ Excess consumption of fructose may also be

associated with gout as a result of the former's propensity to increase uric acid levels.³² Fructose consumption has also been reported as a risk factor for nonalcoholic fatty liver disease.³¹

Compromised immunity.

High blood sugar levels may also render individuals more susceptible to frequent and/or serious infections.³³ Both Type 1 and Type 2 diabetes have been found to significantly increase the risk of experiencing more severe complications from COVID-19 infection.³⁴

Oral disease. Research suggests sugar consumption also has a direct relationship with oral health, specifically pertaining to the formation of dental caries, as the presence of sugars—especially sucrose,^{35,36} which is fermentable—disrupts the pH in the mouth, resulting in an oral environment more favorable to those bacteria that produce dental biofilm.

Mood and cognitive dysfunction. Knüppel et al³⁷ documented an adverse effect of sugar intake on mental health, particularly noting an increase in incident mood disorders in men.

Seetharaman et al,³⁸ using data from the Swedish Adoption/Twin Study of Aging, found that high blood glucose levels correlated with poorer overall performance in perceptual speed as well as greater rates of cognitive decline in general, perceptual

mental speed, verbal ability, and spatial ability scores. The same study reported that diet-based glycemic load was correlated with poorer overall performance in both perceptual speed and spatial ability.

Francis et al³⁹ found that a diet high in fat and refined sugar (HFS) was associated with poorer performance on hippocampal-sensitive memory tasks; a second experiment clarified that this effect is specific to hippocampal functioning and does not extend to measures of prefrontal cortex function. Also, in a laboratory-based test of food intake, the HFS-rich diet groups were less accurate when attempting to recall what they had previously eaten and demonstrated reduced sensitivity to internal signals of hunger and satiety.³⁹

Cancer. Some research has attempted to discern sugar's role in cancer formation. In a French study, Debras et al⁴⁰ noted that consumption of diets with a higher glycemic load (e.g., those containing bread), which is a measure of how rapidly a specific carbohydrate food raises blood sugar, was associated with a higher overall risk for cancer, specifically postmenopausal breast cancer.


Sieri et al⁴¹ reported similar results, finding that diets with a higher glycemic load appeared to inflate the risk of breast cancer, especially in premenopausal women and

Continued on page 10

SWEET NEWS FOR PEOPLE WITH DIABETES

While the sugar content, whether naturally occurring or added during food processing, of many foods can increase blood sugar levels in the body,¹ this is not true in every case. For example, **monk fruit**—a small, round fruit grown in southeast Asia—contains natural sugars such as fructose, but it primarily gains its sweetness from mogroside V, a type of glycoside, which can be extracted for use as a food additive.² Though glycosides are compounds in which sugar is bound to another functional group by way of a glycosidic bond,³ some research in diabetic rats indicates that monk fruit extract may have an antihyperglycemic effect⁴ and may limit diabetic complications associated with oxidative stress.^{4,5} Ban et al⁶ similarly reported that diabetic rats fed yogurt sweetened with monk fruit showed greater blood glucose regulation and a significant reduction in both insulin resistance and glycosylated hemoglobin concentration compared to those fed yogurt sweetened with sucrose.

Stevia gains its sweetness from the actions of an enzyme, uridine diphosphate-dependent glucosyltransferase, which catalyzes the addition of branched glucosides to compounds (primarily stevioside and rebaudioside A) known as steviol glycosides.⁷ According to Lee et al,⁸ both steviol glycosides and their glucosylated derivatives demonstrate antihyperglycemic effects by activating glucose-induced insulin secretion. Chang et al⁹ reported that oral administration of stevioside improves insulin sensitivity in rats. Research has also indicated that stevia may also have preferential effects in people with diabetes; for example, Gregersen et al¹⁰ found that stevioside reduced postprandial blood glucose levels in individuals with Type 2 diabetes, and Rashad et al¹¹ observed that stevioside supplementation for 24 weeks



improved glycemic control, fasting plasma glucose, two-hour plasma glucose, fasting serum insulin, Homeostasis Model Assessment of Insulin Resistance score, and hemoglobin A1c concentration in people with diabetes.

In addition, at least seven **naturally occurring “sweet” proteins** are known to exist—thaumatin, monellin, mabinlin, pentadin, brazzein, curculin, and miraculin.¹² These proteins may be sourced from various fruits in Africa and Asia,¹² and commercialization efforts are ongoing.¹³

SOURCES

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2010;33(Suppl 1):S62–S69.
2. Shivani, Thakur BK, Mallikarjun CP, et al. Introduction, adaptation and characterization of monk fruit (*Siraitia grosvenorii*): a non-caloric new natural sweetener. *Sci Rep*. 2021;11:6205.
3. Onaolapo AY, Onaolapo OJ. Herbal beverages and brain function in health and disease. In: Grumezescu AM, Holban AM. *Functional and Medicinal Beverages*. Vol 11. Cambridge, MA: Academic Press; 2019: 313–349.
4. Qi X-Y, Chen W-J, Zhsang L-Q, Xie B-J. Mogrosides extract from *Siraitia grosvenorii* scavenges free radicals in vitro and lowers oxidative stress, serum glucose, and lipid levels in alloxan-induced diabetic mice. *Nutr Res*. 2008;28(4):278–284.
5. Suzuki YA, Tomoda M, Murata Y, Inui H, Sugiura M, Nakano Y. Antidiabetic effect of long-term supplementation with *Siraitia grosvenorii* on the spontaneously diabetic Goto-Kakizaki rat. *Br J Nutr*. 2007;97(4):770–775.
6. Ban Q, Cheng J, Sun X, et al. Effects of a synbiotic yogurt using monk fruit extract as sweetener on glucose regulation and gut microbiota in rats with type 2 diabetes mellitus. *J Dairy Sci*. 2020;103(4):2956–2968.
7. Li Y, Zhu W, Cai J, et al. The role of metabolites of steviol glycosides and their glucosylated derivatives against diabetes-related metabolic disorders. *Food Funct*. 2021;12(18):8248–8259.
8. Lee SG, Salomon E, Yu O, Jez JM. Molecular basis for branched steviol glucoside biosynthesis. *Proc Natl Acad Sci U S A*. 2019;116(26):13131–13136.
9. Chang J-C, Wu MC, Liu I-M, Cheng J-T. Increase of insulin sensitivity by stevioside in fructose-rich chow-fed rats. *Horm Metab Res*. 2005;37(10):610–616.
10. Gregersen S, Jeppesen PB, Holst JJ, Hermansen K. Antihyperglycemic effects of stevioside in type 2 diabetic subjects. *Metabolism*. 2004;53(1):73–76.
11. Rashad NM, Abdelsamad MAE, Amer AM, Sitohy MZ, Mousa MM. The impact of stevioside supplementation on glycemic control and lipid profile in patients with type 2 diabetes: a controlled clinical trial. *Egypt J Intern Med*. 2019;31:22–30.
12. Kant R. Sweet proteins—potential replacement for artificial low calorie sweeteners. *Nutr J*. 2005;4:5.
13. Joseph JA, Skkermans S, Nimmegeers P, Van Impe JFM. Bioproduction of the recombinant sweet protein thaumatin: current state of the art and perspectives. *Front Microbiol*. 2019;8:10:695. [NHR](#)

Continued from page 8

those with body mass index values of less than 25mg/m².

Laguna et al⁴² linked simple sugar intake in drinks and fruit juice with an increased risk of both overall cancer incidence and mortality and all-cause mortality.

Finally, a 2017 report based on internal documents from a research project funded by the Sugar Research Foundation in the 1960s revealed that sucrose consumption was associated with elevated levels of beta-glucuronidase, an enzyme previously associated with bladder cancer in humans.⁴³

Artificial and sugar alcohol sweeteners. Of note, the aforementioned studies focused on natural and processed sugars and did not include artificial (also known as no- or low-calorie) sweeteners (e.g., aspartame, sucralose) or sugar alcohols, (e.g., xylitol, maltitol, erythritol), which have their own health effects. Artificial sweeteners, which impart sweetness without the calories, could initially facilitate a modest amount of weight loss,⁴⁴ but over time may lead to weight gain by disrupting the brain's association between sweetness and caloric intake.⁴⁵ Artificial sweeteners have also been linked to shifts in the gut microbiota, which may promote antibiotic resistance⁴⁷ or even render certain bacteria pathogenic.⁴⁷

Sugar alcohols are a kind of carbohydrate that raises the blood sugar less significantly

than traditional sugars, potentially making them a good alternative; Mohsenpour et al⁴⁸ reported that a mixture of sugars and a sugar alcohol (lactose, fructose, sucrose, and erythritol) led to improved blood glucose levels compared to the same amount of glucose or sucrose, without any significant adverse effects. However, sugar alcohols have been linked to irritable bowel syndrome.⁴⁹

GUIDELINES AND MOVING FORWARD

Both the 2020 to 2025 Dietary Guidelines for Americans⁵⁰ and the World Health Organization⁵¹ recommend that consumption of added sugar should compose no more than 10 percent of an adult's daily calorie count. The American Heart Association⁵² recommends limiting the amount of added sugars to not more than half of one's daily discretionary calorie allowance (i.e., no more than 100 calories per day for women and no more than 150 calories per day for men [or ~6 and ~9 teaspoons per day, respectively]). However, although Powell et al⁵³ documented a notable decline in calories from added sugars between 2003 and 2012 following a significant increase between 1977 and 2003, no further decline occurred from 2003 to 2012, and added sugar intake levels remained above the recommended level of 10 percent of the

Key Takeaways

- Sugar, as a type of carbohydrate, provides energy to the body, and it may be found in both simple or complex and natural or processed (added) forms.
- Dysfunction in the body's processing of sugars as a result of disease, genetics, medication, or injury leads to blood sugar levels that are too low or too high, which may lead to further complications.
- Excess sugar intake, which can overwhelm the body's processing efforts, can also lead to disease.
- It is recommended that added sugars compose no more than 6% to 10% of an adult's daily calorie count.
- Sugar consumption in the United States remains too high, although it has decreased from decades ago.
- Artificial sweeteners and sugar alcohols are alternatives to traditional sugars and carry their own risks and benefits.

total energy intake as of 2016. Indeed, the 2020 to 2025 Dietary Guidelines for Americans⁵⁰ suggest that 80 percent of men and 77 percent of women in the United States still exceed the recommended 10 percent limitation for added sugar intake.

Editor's note: Please consult with your physician or nutritionist regarding sugar intake and what kind of diet is best for you.

SOURCES

1. Holesh JE, Aslam S, Martin A. Physiology, carbohydrates. [Updated 2021 Jul 26]. In: StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; 2021.
2. Morris AL, Mohiuddin SS. Biochemistry, Nutrients. [Updated 2021 May 12]. In: StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; 2021.
3. Digestion and absorption of carbohydrates. In: University of Hawaii at Mānoa Food Science and Human Nutrition Program. Human Nutrition [Deprecated]. Honolulu, Hawaii: University of Hawaii at Mānoa. <http://pressbooks-dev.oer.hawaii.edu/humannutrition/chapter/digestion-and-absorption-of-carbohydrates/>. Accessed 28 Oct 2021.
4. Mathew P, Thoppil D. Hypoglycemia. [Updated 2021 Jan 13]. In: StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; 2021.
5. Brutsaert EF. Hypoglycemia. <https://www.merckmanuals.com/home/hormonal-and-metabolic-disorders/diabetes-mellitus-dm-and-disorders-of-blood-sugar-metabolism/hypoglycemia>. Accessed 3 Nov 2021.
6. Mouri MI, Badireddy M. Hyperglycemia. [Updated 2021 May 10]. In: StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; 2021.
7. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. *Diabetes Care*. 2020;43(Suppl 1):S14–S31.
8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2010;33(Suppl 1):S62–S69.
9. Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. *Diabetes Metab Syndr Obes*. 2014;7:587–591.
10. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care*. 2010;33(3):676–682.
11. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. *Endocr Pract*. 2015;21 Suppl 1(Suppl 1):1–87.
12. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. *JAMA*. 2021;326(8):736–743.
13. US Preventive Services Task Force; Davidson KW, Barry MJ. Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021;326(6):531–538.
14. Institute of Food Technologists. Sugars: a scientific overview. <https://www.ift.org/career-development/learn-about-food-science/food-facts/food-facts-food-ingredients-and-additives/sugars-a-scientific-overview>. Accessed 3 Nov 2021.
15. Malik V. Are certain types of sugars healthier than others?. <https://www.health.harvard.edu/blog/are-certain-types-of-sugars-healthier-than-others-2019052916699>. Accessed 3 Nov 2021.
16. Lee BM, Wolever TM. Effect of glucose, sucrose and fructose on plasma glucose and insulin responses in normal humans: comparison with white bread. *Eur J Clin Nutr*. 1998;52(12):924–928.
17. Evans RA, Frese M, Romero J, et al. Fructose replacement of glucose or sucrose in food or beverages lowers postprandial glucose and insulin without raising triglycerides: a systematic review and meta-analysis. *Am J Clin Nutr*. 2017;106(2):506–518.
18. Yunker AG, Luo S, Jones S, et al. Appetite-regulating hormones are reduced after oral sucrose vs glucose: influence of obesity, insulin resistance, and sex. *J Clin Endocrinol Metab*. 2021;106(3):654–664.
19. Teff LK, Elliott SS, Tschöp M, et al. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. *J Clin Endocrinol Metab*. 2004;89(6):2963–2972.
20. Malik VS, Li Y, Pan A, et al. Long-term consumption of sugar-sweetened and artificially sweetened beverages and risk of mortality in US adults. *Circulation*. 2019;139(18):2113–2125.
21. Hu FB, Malik VS. Sugar-sweetened beverages and risk of obesity and type 2 diabetes: epidemiologic evidence. *Physiol Behav*. 2010;100(1):47–54.
22. Yin J, Zhu Y, Malik V, et al. Intake of sugar-sweetened and low-calorie sweetened beverages and risk of cardiovascular disease: a meta-analysis and systematic review. *Adv Nutr*. 2021;12(1):89–101.
23. Kim Y, Je Y. Prospective association of sugar-sweetened and artificially sweetened beverage intake with risk of hypertension. *Review Arch Cardiovasc Dis*. 2016;109(4):242–253.
24. Janzi S, Ramne S, González-Padilla E, et al. Associations between added sugar intake and risk of four different cardiovascular diseases in a Swedish population-based prospective cohort study. *Front Nutr*. 2020;7:603653.
25. Swaminathan S, Dehghan M, Raj JM. Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study. *BMJ*. 2021;372:m4948.
26. Musa-Veloso K, Noori D, Venditti C, et al. A systematic review and meta-analysis of randomized controlled trials on the effects of oats and oat processing on postprandial blood glucose and insulin responses. *J Nutr*. 2021;151(2):341–351.
27. Meng Y, Li S, Khan J, et al. Sugar- and artificially sweetened beverages consumption linked to type 2 diabetes, cardiovascular diseases, and all-cause mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. *Nutrients*. 2021;13(8):2636.
28. Liman MNP, Jialal I. Physiology, Glycosuria. [Updated 2021 Mar 24]. In: StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; 2021.
29. Tavafi M. Complexity of diabetic nephropathy pathogenesis and design of investigations. *J Renal Inj Prev*. 2013;2(2):59–62.
30. Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: prevention and management. *J Res*


- Med Sci.* 2015;20(11):1112–1120.
31. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. *J Hepatol.* 2008;48(6):993–999.
 32. Rho YH, Zhu Y, Choi HK. The epidemiology of uric acid and fructose. *Semin Nephrol.* 2011;31(5):410–419.
 33. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. *Indian J Endocrinol Metab.* 2012;16(Suppl1):S27–S36.
 34. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. *Lancet Diabetes Endocrinol.* 2020;8(10):823–833.
 35. Du Q, Fu M, Zhou Y, et al. Sucrose promotes caries progression by disrupting the microecological balance in oral biofilms: an *in vitro* study. *Sci Rep.* 2020;10(1):2961.
 36. Paes Leme AF, Koo H, Bellato CM, Bedi G, Cury JA. The role of sucrose in cariogenic dental biofilm formation—new insight. *J Dent Res.* 2006;85(10):878–887.
 37. Knüppel A, Shipley MJ, Llewellyn CH, Brunner EJ. Sugar intake from sweet food and beverages, common mental disorder and depression: prospective findings from the Whitehall II study. *Sci Rep.* 2017;7:6287.
 38. Seetharaman S, Andel R, McEvoy C, et al. Blood glucose, diet-based glycemic load and cognitive aging among dementia-free older adults. *J Gerontol A Biol Sci Med Sci.* 2015;70(4):471–479.
 39. Francis HM, Stevenson RJ. Higher reported saturated fat and refined sugar intake is associated with reduced hippocampal-dependent memory and sensitivity to interoceptive signals. *Behav Neurosci.* 2011;125(6):943–955.
 40. Debras C, Chazelas E, Srour B, et al. Glycaemic index, glycaemic load and cancer risk: results from the prospective NutriNet-Santé cohort [published online ahead of print . *Int J Epidemiol.* September 7, 2021].
 41. Sieri S, Pala V, Brighenti F, et al. Dietary glycemic index, glycemic load, and the risk of breast cancer in an Italian prospective cohort study. *Am J Clin Nutr.* 2007;86(4):1160–1166.
 42. Laguna JC, Alegret M, Cofán M, et al. Simple sugar intake and cancer incidence, cancer mortality and all-cause mortality: a cohort study from the PREDIMED trial. *Clin Nutr.* 2021;40(10):5269–5277.
 43. Kearns CE, Apollonio D, Glantz SA. Sugar industry sponsorship of germ-free rodent studies linking sucrose to hyperlipidemia and cancer: An historical analysis of internal documents. *PLoS Biol.* 2017;15(11):e2003460.
 44. Miller PE, Perez V. Low-calorie sweeteners and body weight and composition: a meta-analysis of randomized controlled trials and prospective cohort studies. *Am J Clin Nutr.* 2014;100(3):765–777.
 45. Davidson TL, Martin AA, Clark K, Swithers SE. Intake of high-intensity sweeteners alters the ability of sweet taste to signal caloric consequences: implications for the learned control of energy and body weight regulation. *Q J Exp Psychol (Hove).* 2011;64(7):1430–1441.
 46. Yu Z, Wang Y, Lu Ji, et al. Nonnutritive sweeteners can promote the dissemination of antibiotic resistance through conjugative gene transfer. *ISME J.* 2021;15(7):2117–2130.
 47. Shil A, Chichger H. Artificial sweeteners negatively regulate pathogenic characteristics of two model gut bacteria, *E. coli* and *E. faecalis*. *Int J Mol Sci.* 2021;22(10):5228.
 48. Mohsenpour MA, Kaseb F, Nazemian R, et al. The effect of a new mixture of sugar and sugar-alcohols compared to sucrose and glucose on blood glucose increase and the possible adverse reactions: a phase I double-blind, three-way randomized cross-over clinical trial. *Endocrinol Diabetes Nutr (Engl Ed).* 2019;66(10):647–653.
 49. Yao CK, Tan H-L, van Langenberg DR. Dietary sorbitol and mannitol: food content and distinct absorption patterns between healthy individuals and patients with irritable bowel syndrome. *J Hum Nutr Diet.* 2014;27 Suppl 2:263–275.
 50. United States Department of Agriculture. 2020–2025 dietary guidelines for Americans. https://www.dietaryguidelines.gov/sites/default/files/2020-12/Dietary_Guidelines_for_Americans_2020-2025.pdf. Accessed 4 Nov 2021.
 51. The World Health Organization. WHO calls on countries to reduce sugars intake among adults and children. <https://www.who.int/news/item/04-03-2015-who-calls-on-countries-to-reduce-sugars-intake-among-adults-and-children>. Accessed 4 Nov 2021.
 52. American Heart Association. Added sugars. <https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/sugar/added-sugars>. Accessed 4 Nov 2021.
 53. Powell ES, Smith-Taillie LP, Popkin BM. Added sugars intake across the distribution of US children and adult consumers: 1977–2012. *J Acad Nutr Diet.* 2016;116(10):1543–1550.e1.
 54. Taddio A, Shah V, Hancock R, et al. Effectiveness of sucrose analgesia in newborns undergoing painful medical procedures. *CMAJ.* 2008;179(1):37–43.
 55. Chirife J, Herszage L, Joseph A, Kohn ES. *In vitro* study of bacterial growth inhibition in concentrated sugar solutions: microbiological basis for the use of sugar in treating infected wounds. *Antimicrob Agents Chemother.* 1983;23(5):766–773.
 56. Hossain A, Yamaguchi F, Matsuo T, et al. Rare sugar D-allulose: Potential role and therapeutic monitoring in maintaining obesity and type 2 diabetes mellitus. *Pharmacol Ther.* 2015;155:49–59.
 57. Hayashi N, Iida T, Yamada T, et al. Study on the postprandial blood glucose suppression effect of D-psiocese in borderline diabetes and the safety of long-term ingestion by normal human subjects. Study on the postprandial blood glucose suppression effect of D-psiocese in borderline diabetes and the safety of long-term ingestion by normal human subjects. *Biosci Biotechnol Biochem.* 2010;74(3):510–519.
 58. Soterakis J, Iber FL. Increased rate of alcohol removal from blood with oral fructose and sucrose. *Am J Clin Nutr.* 1975;28(3):254–257. NHR

About the Author



Ms. Becker is the managing editor of *The Journal of Innovations in Cardiac Rhythm Management*. She also works as a freelance editor and as a teaching assistant for the George Washington University's Master of Professional Studies in Publishing program.

Superfood Spotlight



A mushroom is a spore-bearing fruiting body of a fungus—a simple definition for a rather complex group of living organisms. Indeed, mushrooms and other fungi are considered neither plant nor animal—they comprise their very own self-named kingdom within the Eukarya domain of the taxonomy of living things.¹ In fact, recent studies indicate that fungi are actually more closely related to animals than to plants and play an essential role across the various ecosystems of the world.² Unfortunately, describing what makes the over six million species of fungi worldwide different from plants and similar to animals, as well as how they impact nature as a whole, is well-beyond the scope of this article. So, you'll just have to settle for this review article in which we focus on edible species of mushrooms and the roles they play in human diet and health.

HISTORY OF MUSHROOM CULTIVATION

Cultivation of mushrooms likely began with the Chinese—Tao Hongjing (456–536 CE) included a commentary on cultivating the

mushroom *Wolfiporia cocos* in *Bencao Jing Jinzhu*, an extension of an extension of the *Shennong Bencao Jing*, the oldest surviving Chinese materia medica, which categorized medicinal uses of 365 herbs.³ In contrast, early cultivation of mushrooms in Europe was documented much later, during the mid-1600s, beginning in abandoned quarries and caves near Paris.⁴ Both Asian and European mushroom cultivation practices were subsequently introduced in the United States in the 1870s.⁵ Today, of about 2,000 species of mushrooms considered safe for consumption, 25 to 35 are widely eaten, and fewer than that are commercially cultivated.^{6,7}

MUSHROOM NUTRIENT COMPOSITION

While the primary mass of most mushroom fruitbodies is water, depending on the species—and even within the same genus—mushrooms contain varying percentages of carbohydrates (3–42% dry matter [DM]), protein (4–44%; maximum, 57.3% DM), and lipids (2–6% DM).⁸ Mushrooms

are low in calories yet contain a variety of vitamins, polyphenols, carotenoids, macroelements, and other bioactive components.^{8,9} In an analysis, the addition of an 84g serving of commonly consumed raw mushrooms (e.g., the white, brown/cremini, and portabella states of *Agaricus bisporus*) to United States (US) Department of Agriculture Food Patterns resulted in a 2- to 3-percent increase in fiber, an 8- to 12-percent increase in potassium, a 12- to 18-percent increase in riboflavin, an 11- to 26-percent increase in niacin, an 11- to 23-percent increase in selenium, and a 16- to 26-percent increase in copper depending upon the pattern type and calorie level but only one-percent or less increase in sodium, a one-percent increase in calories, and no effect on saturated fat or cholesterol.¹⁰ Adding a serving of raw specialty mushrooms (*Pleurotus ostreatus*) also increased dietary vitamin D by 8 to 11 percent and dietary choline by 10 to 16 percent.¹⁰

The nutrient profiles of mushrooms can also vary depending on the environment in which they grow; for example, a comparison of wild and

commercial species of mushrooms revealed that the latter generally contained more fat, less protein, and more sugar. When considering types of vitamin E, higher levels of α -tocopherol but undetectable levels of γ -tocopherol were found in the wild species, and the wild species also contained lower concentrations of monounsaturated fatty acids but higher concentrations of polyunsaturated fatty acids as well as higher concentrations of phenols but a lower concentration of ascorbic acid compared to commercial mushrooms.¹¹ A separate study confirmed the greater phenol content and antioxidant capacity of wild mushrooms compared to commercial mushrooms.¹²

MUSHROOMS AS MEDICINE

Views on the consumption of mushrooms varied across the ancient world; while leading Roman medical practitioners were wary of mushroom consumption due to numerous cases of accidental poisoning and excessive consumption of edible mushrooms leading to indigestion by the populace,¹³ Eastern populations, such as the Chinese, Japanese, and Indians, have long viewed mushrooms as medicinal aids.^{14,15} Today, the health benefits of various mushrooms are known to include antioxidant, prebiotic, antihypertensive, anti-inflammatory, antiviral/antimicrobial, neuroprotective, hepatoprotective, and antitumor/anticancer effects, among others.¹⁶⁻¹⁸

Cardiovascular and metabolic health. Research suggests that edible mushroom consumption may favorably alter metabolic markers (e.g. cholesterol, triglycerides) and

reduce blood pressure,¹⁹⁻²¹ although the effects can differ depending on the mushroom. For example, among spontaneously hypertensive rats (a common animal model of hypertension and cardiovascular disease) in one study, those fed maitake mushrooms (*Grifola frondosa*) experienced a decrease in their total cholesterol level compared to the control group, while those fed shiitake mushrooms (*Lentinus edodes*) experienced a reduction in their free cholesterol level.²⁰ There was no difference in the plasma triglyceride or phospholipid levels between the experimental groups; however, shiitake consumption resulted in a decrease in both very-low-density lipoprotein ("bad") cholesterol and high-density lipoprotein ("good") cholesterol compared to the control group, while maitake consumption elicited a decrease in very-low-density lipoprotein ("bad") cholesterol only.²⁰ Some of the same investigators reported in another study that the blood pressure of spontaneously hypertensive rats was significantly reduced following eight weeks of maitake mushroom consumption, but this effect was not true with shiitake consumption. Moreover, although the investigators affirmed the reduction in plasma-free cholesterol levels and reported reductions in triglyceride and phospholipid levels with shiitake intake, they did not observe reductions in either total or free cholesterol levels or triglyceride and phospholipid levels with the consumption of maitake mushrooms.²¹ Keeping in mind all these findings and that free cholesterol has cytotoxic effects (which may be mitigated by high-

density lipoprotein cholesterol),²² the intake of both mushrooms (ensuring variety) rather than either alone, in combination with other healthy foods (i.e., those that increase high-density lipoprotein cholesterol and phospholipid concentrations on their own), may lead to the best outcome.

Collectively, edible mushrooms appear to support glucose control by a variety of mechanisms, including inhibiting glucose absorption, protecting β -cells (which produce and release insulin in the pancreas) from damage, increasing insulin release, and regulating different relevant pathways in the body.²³ In Type 2 diabetic C57BL/6 mice (which carry a genetic predisposition to develop Type 2 diabetes), oral administration of 250 or 500mg/kg of chaga mushroom (*Inonotus obliquus*) extract significantly alleviated insulin resistance, with a dose-effect relationship noted within a certain range; indeed, the authors reported that the 500mg/kg dose of extract achieved an effect similar to that of the diabetes drug metformin.²⁴ Along these lines, oral administration of 900mg/kg of chaga mushroom in another study led to reductions in fasting blood glucose levels, an improved glucose-tolerance ability, an increased hepatic glycogen level (to better prevent high blood glucose levels), and ameliorated insulin resistance in a Type 2 diabetic mouse model induced by a high-fat diet and streptozotocin (a compound with preferential toxicity toward pancreatic β -cells) compared to diabetic control mice.²⁵

Immune function. Research has attributed the beneficial effects of edible mushrooms on the immune system to their ability to modulate

different cytokine responses. In cancer, maitake, *Ganoderma lucidum* (reishi), *Cordyceps sinensis*, and *Trametes versicolor* (turkey tail) may increase the production of T helper (Th)1 cytokines, such as interferon- γ , which activate death receptors on the surfaces of tumor cells to help Th1 cells locate and kill them.²⁶ Edible Agaricus, maitake, reishi, Cordyceps, and turkey tail mushrooms may also downregulate Th2 cytokines, which reduce Th1 cytokine concentrations, thus showing an additional benefit in treating cancer by maintaining higher concentrations of tumor-destroying Th1 cells.²⁶

Edible mushrooms may also increase the therapeutic efficacy

of mainstay treatments for cancer.²⁶ During chemotherapy, chemotherapeutic agents penetrate and accumulate in tumor cells to induce cell cycle arrest and apoptosis; as such, some edible mushrooms, such as Agaricus spp., may help drugs such as doxorubicin to accumulate intracellularly at greater doses, increasing their therapeutic efficacy.²⁷ Other edible mushrooms, when combined with such drugs, may help to inhibit tumor growth; one study concluded that administering an extract of *Cordyceps sinensis* in combination with cisplatin could inhibit tumor growth,²⁸ and another determined that the combination

of polysaccharide K (a derivative of turkey tail mushrooms) and trastuzumab reduced cell growth in colorectal tumors by 96 percent.²⁹ Mushrooms may also minimize associated undesirable side effects of chemotherapy and radiation therapy, such as nausea, bone marrow suppression, anemia, and insomnia.³⁰


Other research has examined mushroom intake for managing inflammatory conditions. According to a literature search, the various bioactive molecules found in mushrooms, including peptides, polysaccharides, terpenes, sterols, fatty acids, and phenols, may inhibit major proinflammatory biomarkers

Mushrooms and Beta-Glucans

Beta-glucans, a type of polysaccharide found in bacteria, yeasts, fungi, and plants, help to regulate inflammation (e.g., by decreasing levels of pro-inflammatory cytokines¹) and activate or enhance the functional activity of various innate and adaptive immune cell populations, including macrophages, dendritic cells, and lymphocytes.² In cancer, β -glucans may increase counts of M1-phenotype tumor-associated (antitumor) macrophages and decrease counts of M2-phenotype tumor-associated (protumor) macrophages.³ Lentinan, a fungal β -glucan constituent, has shown the ability to prolong cancer patient survival when combined with chemotherapy, compared to chemotherapy alone,^{4,5} and it has also been linked to reductions of systemic inflammatory markers, such as serum C-reactive protein and macrophage inflammatory protein-1 α /chemokine C-C ligand 3, and increases in the anti-inflammatory response markers interleukin-4 and interleukin-10.⁶ Lentinan may also be useful for reversing hyperglycemia in the early and late stages of Type 1 diabetes.⁷

Pleuran, the β -glucan isolated from *Pleurotus ostreatus*, was found to reduce peripheral blood eosinophilia and stabilized serum levels of total immunoglobulin E in children with recurrent respiratory tract infections, which the study investigators suggest is due to its potential antiallergic effect.⁸ According to other research, supplementation with a β -glucan derived from *Aureobasidium pullulans* was effective for the prevention of influenza in mice,⁹ and β -glucan supplementation also led to reduced mortality in a mouse model of influenza.¹⁰ Finally, a comparative study of β -glucans from different sources determined that treating keratinocytes with a β -glucan derived from *Schizophyllum commune* promoted *in-vivo* wound closure.¹¹

SOURCES

- Um MY, Park JH, Gwon SY, Ahn J, Jung CH, Ha TY. Agaricus bisporus attenuates dextran sulfate sodium-induced colitis. *J Med Food*. 2014;17(12):1383-1385.
- Chi-Fung Chan GC-F, Chan WK, Sze DM-Y. The effects of beta-glucan on human immune and cancer cells. *J Hematol Oncol*. 2009;2:25.
- Wang W-J, Wu Y-S, Chen S, Liu C-F, Chen S-N. Mushroom β -glucan may immunomodulate the tumor-associated macrophages in the Lewis lung carcinoma. *Biomed Res Int*. 2015;2015:604385.
- Ina K, Furuta R, Kataoka T, et al. Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy. *World J Clin Oncol*. 2011;2:339-343.
- Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. *Anticancer Res*. 2009;29:2739-2745.
- Dai X, Stanilka JM, Rowe CA, et al. Consuming Lentinula edodes (Shiitake) mushrooms daily improves human immunity: a randomized dietary intervention in healthy young adults. *J Am Coll Nutr*. 2015;34(6):478-487.
- Wu T, Cai Z, Niu F, et al. Lentinan confers protection against type 1 diabetes by inducing regulatory T cell in spontaneous non-obese diabetic mice. *Nutr Diabetes*. 2023 Apr 8;13(1):4.
- Jesenak M, Hrubisko M, Majtan J, Rennerova Z, Banovcin P. Anti-allergic effect of pleuran (β -glucan from *Pleurotus ostreatus*) in children with recurrent respiratory tract infections. *Phytother Res*. 2014;28:471-474.
- Muramatsu D, Iwai A, Aoki S, et al. β -Glucan derived from *Aureobasidium pullulans* is effective for the prevention of influenza in mice. *PLoS One*. 2012;7(7):e41399.
- Vetvicka V, Vetvickova J. Glucan supplementation enhances the immune response against an influenza challenge in mice. *Ann Transl Med*. 2015;3(2):22.
- Seo G, Hyun C, Choi S, Kim YM, Cho M. The wound healing effect of four types of beta-glucan. *Appl Biol Chem*. 2019;62(20). 





Mushrooms and the Central Nervous System

and associated pathways, thus exerting anti-inflammatory effects.³¹ Mushrooms such as chaga,³⁴ maitake,³⁵ and reishi³⁶ also seem to have anti-allergic effects by inhibiting the process of mast cell degranulation (during which mast cells release mediators, such as histamine).

Certain edible mushrooms may also combat viral infection by preventing viral entry or replication and stimulating immune cell responses. Polysaccharides from *Agaricus blazei* Murrill, for example, were found to reduce the cytopathic effects of Western equine encephalitis virus, herpes simplex virus (HSV), and poliovirus in Vero cells (a lineage of cells derived from kidney epithelial cells extracted from an African green monkey).³⁷ A sulfated derivative of a polysaccharide from *Agaricus brasiliensis* Fr. suppressed HSV-1 and HSV-2 cell attachment, cell penetration, and intracellular spread *in vitro*.³⁸ Interestingly, the sulfated derivative in question also displayed a synergistic antiviral effect against HSV when combined with the antiviral drug acyclovir, suggesting the potential of combining edible mushrooms with antiviral medications to improve treatment effects.³⁸

Neuroprotection and neuroregeneration. According to investigators, edible mushrooms could play a role in the prevention³⁹ and treatment^{40,41} of dementia, with various mushroom species displaying the potential to reduce or inhibit the production of beta-amyloid and phosphorylated tau.⁴² However, mushroom consumption may also help to limit or prevent more general

Different edible mushrooms may play a role in the prevention¹ and treatment^{2,3} of dementia by reducing or inhibiting the production of β -amyloid and phosphorylated tau.⁴ One study in which patients with mild Alzheimer's disease were administered either erinacine A-enriched lion's mane capsules or placebo demonstrated a significant reduction in the Cognitive Abilities Screening Instrument scores in the placebo group, a significant improvement in the Mini-mental State Examination scores in the lion's mane group, and a significant difference in Instrumental Activities of Daily Living scores between the two groups after 49 weeks of treatment.² In mice, tests performed to evaluate memory and learning function suggested that lion's mane supplementation prevented the impairments of spatial short-term and visual recognition memory induced by amyloid β 25–35 peptide.⁵

Lion's mane consumption may also benefit patients with depression and anxiety: in a study of 30 women, those who consumed lion's mane cookies for four weeks had reduced scores on the Center for Epidemiologic Studies Depression Scale and Indefinite Complaints Index, compared to those who consumed placebo cookies.⁶ Separately, treatment with psilocybin, a naturally occurring psychedelic substance present in Psilocybe mushrooms, combined with psychedelic psychotherapy, relieved major depressive disorder symptoms in adult patients for up to one year,⁷ and a systematic review and meta-analysis determined that psilocybin was more effective than placebo in treating state (threat-specific) anxiety for up to two weeks and trait (general) anxiety up to six months after treatment.⁸

SOURCES

1. Li I-C, Chang H-H, Lin C-H, et al. Prevention of early Alzheimer's disease by erinacine A-enriched *Hericium erinaceus* mycelia pilot double-blind placebo-controlled study. *Front Aging Neurosci.* 2020;12:155.
2. Yanshree, Yu WS, Fung ML, Lee CW, Lim LW, Wong KH. The monkey head mushroom and memory enhancement in Alzheimer's disease. *Cells.* 2022;11(15):2284.
3. Phan CW, David P, Naidu M, Wong K-H, Sabaratnam V. Therapeutic potential of culinary-medicinal mushrooms for the management of neurodegenerative diseases: diversity, metabolite, and mechanism. *Crit Rev Biotechnol.* 2015;35(3):355–368.
4. Feng L, Cheah IK-M, Ng MM-X, et al. The association between mushroom consumption and mild cognitive impairment: a community-based cross-sectional study in Singapore. *J Alzheimer's Dis.* 2019;68(1):197–203.
5. Mori K, Obara Y, Moriya T, Inatomi S, Nakahata N. Effects of *Hericium erinaceus* on amyloid β (25–35) peptide-induced learning and memory deficits in mice. *Biomed Res.* 2011;32(1):67–72.
6. Nagano M, Shimizu K, Kondo R, et al. Reduction of depression and anxiety by 4 weeks *Hericium erinaceus* intake. *Biomed Res.* 2010;31(4):231–237.
7. Gukasyan N, Davis AK, Barrett FS. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. *J Psychopharmacol.* 2022;36(2).
8. Yu C-L, Yang F-C, Yang S-N, et al. Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis. *Psychiatry Investig.* 2021;18(10):958–967. [NHR](#)

cognitive decline: among 663 participants 60 years of age or older in the Diet and Healthy Aging study in Singapore, those who consumed greater than two portions (>300g) of mushrooms per week had reduced odds of having mild cognitive impairment independent of age, sex, education, cigarette smoking, alcohol consumption, hypertension,

diabetes, heart disease, stroke, physical activities, and social activities.⁴³ Similarly, greater mushroom intake was associated with better scores on certain cognitive performance tests among adults 60 years of age or older from the 2011–2014 U.S. National Health and Nutrition Examination Survey.⁴⁴ Along these lines, a

Poisonous Mushrooms and Medicine

Research has shown that edible mushrooms from a range of genera exert various anticancer treatment effects.¹ In addition, further investigation of α -amanitin, a toxin found in the poisonous *Amanita phalloides* mushroom, as a possible anticancer treatment has progressed with the development of antibody-drug conjugates, allowing for its safe delivery into the body,² and mouse studies have suggested its efficacy in treating colorectal cancer³ and pancreatic cancer,⁴ among others. *In vitro*, the administration of α -amanitin was also shown to inhibit subpopulations of cancer cells that survive in the presence of drugs (i.e., “drug-tolerant colonies”), suggesting its potential to prevent post-treatment cancer relapse.⁵ Separately, illudins, which are terpene compounds derived from the poisonous mushroom *Omphalotus illudens* and related basidiomycetes, are rapidly (<2 hours) cytotoxic to different hematopoietic leukemia and solid tumor cells at pico- to nanomolar concentrations, while normal bone marrow progenitors and fibroblasts require longer exposure times at micro- or millimolar concentrations to experience similar effects,⁶ which may support their development as cancer therapeutics. Importantly, mushrooms should not be used to replace prescribed medications or therapies without prior discussion with a physician.



Antioxidation. Mushrooms contain both primary and secondary antioxidants as well as compounds with antioxidant properties that act as cell signals and/or inducers, leading to alterations in gene expression that activate enzymes to eliminate reactive oxygen species.⁵⁰ Certain mushrooms also inhibit lipid peroxidation, a process in which reactive oxygen species trigger the oxidative deterioration of lipids.⁵⁵ One study determined that mushrooms contain unusually high amounts of ergothioneine and another antioxidant, glutathione, although the levels vary between species: among 13 species tested, maitake (2.41mg/g of dry weight) and *Agrocybe aegerita* (1.92mg/g of dry weight) mushrooms contained the most glutathione, and *Boletus edulis* (7.27mg/g of dry weight) and *Pleurotus citrinopileatus* (3.94mg/g of dry weight) mushrooms contained the most ergothioneine.⁵²

Mushrooms also contain different amounts of other antioxidants, including phenolics, flavonoids, glycosides, polysaccharides, tocopherols, carotenoids, vitamins, minerals, and ascorbic acid.⁵⁰

In a study from Ethiopia, testing of two cultivated (*Pleurotus ostreatus* and shiitake) and five wild (*Laetiporus sulphureus*, *Agaricus campestris*, *Termitomyces clypeatus*, *Termitomyces microcarpus*, and *Tapura letestui*) mushroom species indicated that, among them, *Agaricus campestris* exhibited significant antioxidant potential due to having the highest levels of multiple phenolic compounds, including ferulic acid, gallic acid, and p-hydroxybenzoic acid.⁵³ In another study investigating hot

SOURCES

1. Patel S, Goyal A. Recent developments in mushrooms as anti-cancer therapeutics: a review. *Biotech.* 2012;2(1):1-15.
2. Heidelberg Pharma. A targeted cancer chemotherapy with a new mode of action. Available at: <https://www.nature.com/articles/d43747-020-01103-2>. Accessed April 30, 2023.
3. Liu Y, Zhang X, Han C, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. *Nature.* 2015;520(7549):697-701.
4. Moldenhauer G, Salnikov AV, Luttgau S, Herr I, Anderl J, Faulstich H. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. *J Natl Cancer Inst.* 2012;104(8):622-634.
5. Kume K, Ikeda M, Miura S, et al. α -amanitin restrains cancer relapse from drug-tolerant cell subpopulations via TAF15. *Sci Rep.* 2016;6:25895.
6. Kelner MJ, McMorris TC, Montoya MA, et al. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells. *Cancer Chemother Pharmacol.* 1997;40:65-71. **NHR**

study from western Norway that recruited elderly participants (70–74 years) from the general population confirmed a linear increase in the dose-response association between mushroom consumption and cognitive test performance.⁴⁵

The neuroprotective effects of edible mushrooms may be attributable to the amino acid ergothioneine, which the human body cannot synthesize itself but can source from certain foods, including mushrooms. Notably, however, whole-blood concentrations of ergothioneine were found to decline

significantly after 60 years of age,⁴⁶ and ergothioneine levels were lower in individuals with mild cognitive impairment (plasma)⁴⁶ or Parkinson's disease (serum)⁴⁷ compared to age-matched healthy individuals. Some edible mushrooms, such as *Hericium erinaceus* (lion's mane), contain compounds that may also boost hippocampal memory by encouraging nerve growth.⁴⁸ The antioxidants in mushrooms may also help to control oxidative stress levels and maintain antioxidant defenses to prevent age-related neurodegeneration.⁵³

water extracts of *Agaricus*, *Antrrodia*, *Auricularia*, *Coprinus*, *Cordyceps*, *Hericium*, *Grifola*, *Ganoderma*, *Lentinus*, *Phellinus*, and *Trametes* mushrooms, researchers reported concentrations of polyphenolic compounds and polysaccharides to be responsible for their high antioxidant potential, with *Ganoderma* mushrooms exhibiting the greatest antioxidant potential.⁵⁴ In another study, among 16 of the most popular edible species of wild-growing mushrooms, *Boletus chrysenteron* and *Boletus edulis* had high polyphenol contents and antioxidant activity.⁵⁵

SUPPLEMENTING WITH MUSHROOMS

As an alternative to consuming mushrooms during meals, mushroom supplements are available and often combine multiple mushrooms that are heat-treated and milled to disrupt the chitinous cell wall matrix and increase the surface area for digestion and absorption.⁵⁶ When choosing a mushroom supplement, however, one may need to consider whether the mushroom mycelium (a web of fibers found underground) or the fruiting body (the cap and stalk) provides better nutrition, as different supplement companies opt to include one, the other, or both.⁵⁶ Ultimately, to secure one's preferred nutrient profile, the choice between a mycelium or fruiting body supplement may depend on the mushroom: one study comparing the antioxidant properties of commonly cultivated mushrooms between *in-vivo* (fruiting body) and *in-vitro* (mycelium) samples determined that the mushroom species with the greatest antioxidant potential

was the brown *Agaricus bisporus*, while, among the mycelium samples, shiitake mushrooms showed the highest antioxidant activity.⁵⁷ Similarly, other studies reported that the mycelium of *Pleurotus ostreatus* had greater concentrations of ergosterol and phenolic compounds than the corresponding fruiting body,⁵⁸ while fruiting bodies of *Agaricus bisporus*, when compared to both farm (old mycelium) and *in-vitro* (young) mycelium, contained higher levels of different phenols and ergothioneine.⁵⁹ In other cases, both parts of the same mushroom may contain unique nutrients: take, for example, lion's mane, where hericenones were isolated from the fruiting body but erinacines were isolated from the mycelium.⁶⁰

A NOTE OF CAUTION

Like other foods, edible mushrooms should be consumed after being properly prepared. Cutaneous reactions (e.g., shiitake dermatitis^{61,62}) have been documented following the ingestion of raw or undercooked mushrooms. Raw *Agaricus* mushrooms also contain agaritine,^{63,64} a hydrazine-derivative mycotoxin with carcinogenic properties in which concentrations may be reduced—although not removed entirely—by exposing the mushrooms to heat.⁶³ Similarly, *Agaricus bisporus* and another edible mushroom, *Gyromitra esculenta*, contain hydrazine analogs, which were found in an animal study following administration in drinking water continuously for life to directly or indirectly (by way of their derivatives) to cause tumors in various tissues in Swiss mice and Syrian (golden) hamsters.⁶⁵ Of course, serious

anaphylactic reactions can occur in susceptible individuals following the consumption of even the most commonly eaten edible mushrooms.⁶⁶ Finally, mushroom supplementation should be monitored in individuals with more complex health conditions; for example, authors of a case series report of three Japanese patients with cancer suggested a causal relationship between the patients' severe hepatic damage and their use of *Agaricus blazei* extract as alternative medicine.⁶⁷


Editor's note. Please discuss the consumption of mushrooms or mushroom supplements with your primary care practitioner.

SOURCES

1. Canadian Forest Service website. Forest mushrooms. What is a mushroom? <https://www.for.gov.bc.ca/hfp/publications/00029/mushwhat.htm>. Accessed 16 May 2023.
2. Lovett B. Three reasons fungi are not plants. 6 Jan 2021. American Society for Microbiology website. <https://asm.org/Articles/2021/January/Three-Reasons-Fungi-Are-Not-Plants#:~:text=This%20is%20our%20final%20reason,related%20to%20animals%20than%20plants>. Accessed 16 May 2023.
3. Lu D. Ancient Chinese people's knowledge of macrofungi as medicinal material during the period from 581 to 979 AD. *Int J Med Mushrooms*. 2014;16(2):189-204.
4. Bertelsen, C.D. *Mushroom: A Global History*; Reaktion Books: London, UK, 2013
5. Bunyard, B. *A History of Mushroom Cultivation in America Timeline*; FUNGI: Basel, Switzerland, 2021; pp. 24-25
6. Valverde ME, Hernández-Pérez T, Paredes-López O. Edible mushrooms: improving human health and promoting quality life. *Int J Microbiol*. 2015;2015:376387.
7. Bhambrani A, Srivastava M, Mahale VG, Mahale S, Karn SK. Mushrooms as potential sources of active metabolites and medicines. *Front Microbiol*. 2022;13:837266.
8. Malinowski R, Sotek Z, Stasińska M, Malinowska K, Radke P, Malinowska A. Bioaccumulation of macronutrients in edible mushrooms in various habitat conditions of NW Poland—role in the human diet. *Int J Environ Res Public Health*. 2021;18(16):8881.
9. Kumar K, Mehra R, Guiné RPF, et al. Edible mushrooms: a comprehensive review on bioactive compounds with health benefits and processing aspects. *Foods*. 2021;10(12):2996.

10. Agarwal S, Fulgoni III VL. Nutritional impact of adding a serving of mushrooms to USDA Food Patterns – a dietary modeling analysis. *Food Nutr Res.* 2021;65:10.29219/fnr.v65.5618.
11. Barros L, Cruz T, Baptista P, Estevinho LM, Ferreira ICFR. Wild and commercial mushrooms as source of nutrients and nutraceuticals. *Food Chem Toxicol.* 2008;46(8):2742–2747.
12. Alvarez-Parrilla E, de la Rosa LA, Martínez NR, Aguilar González GA. Total phenols and antioxidant activity of commercial and wild mushrooms from Chihuahua, Mexico. *Cienc Tecnol Aliment.* 2007;5(5):329–334.
13. Buller AHR. The fungus lore of the Greeks and Romans. *Trans Br Mycol Soc.* 1914–1916;5:21–66.
14. Varghese R, Dalvi YB, Lamrood PY, Shinde BP, Nair CCK. Historical and current perspectives on therapeutic potential of higher basidiomycetes: an overview. *3 Biotech.* 2019;9(10):362.
15. Lee K-H, Morris-Natschke SL, Yang X, et al. Recent progress of research on medicinal mushrooms, foods, and other herbal products used in traditional Chinese medicine. *J Tradit Complement Med.* 2012;2(2):84–95.
16. Jayachandran M, Xiao J, Xu B. A critical review on health promoting benefits of edible mushrooms through gut microbiota. *Int J Mol Sci.* 2017;18(9):1934.
17. Zhang J-J, Li Y, Zhou T, et al. Bioactivities and health benefits of mushrooms mainly from China. *Molecules.* 2016;21(7):938.
18. Bhambri A, Srivastava M, Mahale VG, Mahale S, Karn SK. Mushrooms as potential sources of active metabolites and medicines. *Front Microbiol.* 2022;13:837266.
19. Krittanawong C, Isath A, Hahn J, et al. Mushroom consumption and cardiovascular health: a systematic review. *Am J Med.* 2021;134(5):637–642.e2.
20. Kabir Y, Yamaguchi M, Kumura S. Effect of shiitake (*Lentinus edodes*) and maitake (*Grifola frondosa*) mushrooms on blood pressure and plasma lipids of spontaneously hypertensive rats. *J Nutr Sci Vitaminol (Tokyo).* 1987;33(5):341–346.
21. Kabir Y, Kumura S. Dietary mushrooms reduce blood pressure in spontaneously hypertensive rats (SHR). *J Nutr Sci Vitaminol (Tokyo).* 1989;35(1):91–94.
22. Kellner-Weibel G, Luke SJ, Rothblat GH. Cytotoxic cellular cholesterol is selectively removed by apoA-I via ABCA1. *Atherosclerosis.* 2003;171(2):235–243.
23. Lo H-C, Wasser SP. Medicinal mushrooms for glycemic control in diabetes mellitus: history, current status, future perspectives, and unsolved problems (review). *Int J Med Mushrooms.* 2011;13(5):401–26.
24. Zhang Z, Liang X, Tong L, et al. Effect of *Inonotus obliquus* (Fr.) Pilat extract on the regulation of glycolipid metabolism via PI3K/Akt and AMPK/ACC pathways in mice. *J Ethnopharmacol.* 2021;273:113963.
25. Wang J, Wang C, Li S, et al. Anti-diabetic effects of *Inonotus obliquus* polysaccharides in streptozotocin-induced type 2 diabetic mice and potential mechanism via PI3K-Akt signal pathway. *Biomed Pharmacother.* 2017;95:1669–1677.
26. Guggenheim AG, Wright KM, Zwickey HL. Immune modulation from five major mushrooms: application to integrative oncology. *Integr Med (Encinitas).* 2014;13(1):32–44.
27. Lee JS, Hong EK. *Agaricus blazei* Murill enhances doxorubicin-induced apoptosis in human hepatocellular carcinoma cells by NFκB-mediated increase of intracellular doxorubicin accumulation. *Int J Oncol.* 2011;38(2):401–408.
28. Ji N-F, Yao L-S, Li Y, He W, Yi K-S, Huang M. Polysaccharide of *Cordyceps sinensis* enhances cisplatin cytotoxicity in non-small cell lung cancer H157 cell line. *Integr Cancer Ther.* 2011;10(4):359–367.
29. Ohwada S, Ogawa T, Makita F, et al. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. *Oncol Rep.* 2006;15(4):861–868.
30. Park H-J. Current uses of mushrooms in cancer treatment and their anticancer mechanisms. *Int J Mol Sci.* 2022;23(18):10502.
31. Rowaiye A, Wilfred OI, Onuh OA, et al. Modulatory Effects of mushrooms on the inflammatory signaling pathways and pro-inflammatory mediators. *Clin Complement Med Pharmacol.* 2022;2(4):100037.
32. Mishra SK, Kang J-H, Kim D-K, Oh SH, Kim MK. Orally administered aqueous extract of *Inonotus obliquus* ameliorates acute inflammation in dextran sulfate sodium (DSS)-induced colitis in mice. *J Ethnopharmacol.* 2012;143(2):524–532.
33. Um MY, Park JH, Gwon SY, Ahn J, Jung CH, Ha TY. *Agaricus bisporus* attenuates dextran sulfate sodium-induced colitis. *J Med Food.* 2014;17(12):1383–1385.
34. Nguyet TMN, Lomonova M, Le BV, et al. The mast cell stabilizing activity of Chaga mushroom critical for its therapeutic effect on food allergy is derived from inotodiol. *Int Immunopharmacol.* 2018;54:286–295.
35. Kawai J, Mori K, Hirasawa N. *Grifola frondosa* extract and ergosterol reduce allergic reactions in an allergy mouse model by suppressing the degranulation of mast cells. *Biosci Biotechnol Biochem.* 2019;83(12):2280–2287.
36. Tasaka K, Akagi M, Miyoshi K, Mio M, Makino T. Anti-allergic constituents in the culture medium of *Ganoderma lucidum*. (I). Inhibitory effect of oleic acid on histamine release. *Agents Actions.* 1988;23(3–4):153–156.
37. Sorimachi K, Ikehara Y, Maezato G, et al. Inhibition by *Agaricus blazei* Murill fractions of cytopathic effect induced by western equine encephalitis (WEE) virus on VERO cells in vitro. *Biosci Biotechnol Biochem.* 2001;65(7):1645–647.
38. de Sousa Cardozo FTG, Camellini CM, Mascarello A, et al. Antihyperlipidemic activity of a sulfated polysaccharide from *Agaricus brasiliensis* mycelia. *Antiviral Res.* 2011;92(1):108–114.
39. Zhang S, Tomata Y, Sugiyama K, Sugawara Y, Tsuji I. Mushroom consumption and incident dementia in elderly Japanese: the Ohsaki Cohort 2006 study. *J Am Geriatr Soc.* 2017;65(7):1462–1469.
40. Li I-C, Chang H-H, Lin C-H, et al. Prevention of early Alzheimer's disease by erinacine A-enriched *Hericium erinaceus* mycelia pilot double-blind placebo-controlled study. *Front Aging Neurosci.* 2020;12:155.
41. Yanshree, Yu WS, Fung ML, Lee CW, Lim LW, Wong KH. The monkey head mushroom and memory enhancement in Alzheimer's disease. *Cells.* 2022;11(15):2284.
42. Phan CW, David P, Naidu M, Wong K-H, Sabaratnam V. Therapeutic potential of culinary-medicinal mushrooms for the management of neurodegenerative diseases: diversity, metabolite, and mechanism. *Crit Rev Biotechnol.* 2015;35(3):355–368.
43. Feng L, Cheah IK-M, Ng MM-X, et al. The association between mushroom consumption and mild cognitive impairment: a community-based cross-sectional study in Singapore. *J Alzheimer's Dis.* 2019;68(1):197–203.
44. Ba DM, Gao X, Al-Shaar L, et al. Mushroom intake and cognitive performance among US older adults: the National Health and Nutrition Examination Survey, 2011–2014. *Br J Nutr.* 2022;128(11):2241–2248.
45. Nurk E, Refsum H, Drevon CA, et al. Cognitive performance among the elderly in relation to the intake of plant foods: the Hordaland Health study. *Br J Nutr.* 2010;104(8):1190–1201.
46. Cheah IK, Feng L, Tang RMY, Lim KHC, Halliwell B. Ergothioneine levels in an elderly population decrease with age and incidence of cognitive decline; a risk factor for neurodegeneration?. *Biochem Biophys Res Commun.* 2016;478(1):162–167.
47. Hatano T, Saiki S, Okuzumi A, Mohny RP, Hattori N. Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. *J Neurol Neurosurg Psychiatry.* 2016;87(3):295–301.
48. Martínez-Mármol R, Chai Y, Conroy JN, et al. Hericin derivatives activates a pan-neurotrophic pathway in central hippocampal neurons converging to ERK1/2 signaling enhancing spatial memory [online ahead of print January 20, 2023]. *J Neurochem.*
49. Liuzzi GM, Petrogliola T, Latronico T, Crescenzi A, Rossano R. Antioxidant compounds from edible mushrooms as potential candidates for treating age-related neurodegenerative diseases. *Nutrients.* 2023;15(8):1913.
50. Kozarski M, Klaus A, Jakovljevic D, et al. Antioxidants of edible mushrooms. *Molecules.* 2015;20(10):19489–19525.
51. 55Cheung LM, Cheung PCK. Mushroom extracts with antioxidant activity against lipid peroxidation. *Food Chem.* 2005;89(3):403–409.
52. Martínez-Mármol R, Chai YJ, Conroy JN, et al. Hericin derivatives activates a pan-neurotrophic pathway in central hippocampal neurons converging to ERK1/2 signaling enhancing spatial memory (online ahead of print January 20, 2023). *J Neurochem.*
53. Woldegiorgis AZ, Abate D, Haki GD, Ziegler

GR. Antioxidant property of edible mushrooms collected from Ethiopia. *Food Chem.* 2014;157:30-36.

54. Song W, van Griensven LJ, Pro- and antioxidative properties of medicinal mushroom extracts. *Int J Med Mushrooms.* 2008;10:315-324.
55. Witkowska AM, Zujko ME, Mirończuk-Chodakowska I. Comparative study of wild edible mushrooms as sources of antioxidants. *Int J Med Mushrooms.* 2011;13(4):335-341.
56. Om. Mycelium vs. fruiting body: the power of the whole mushroom. Available at: <https://ommushrooms.com/pages/mycelium-vs-fruiting-body-m2>. Accessed April 26, 2023.
57. Reis FS, Martins A, Barros L, Ferreira ICFR. Antioxidant properties and phenolic profile of the most widely appreciated cultivated mushrooms: a comparative study between in vivo and in vitro samples. *Food Chem Toxicol.* 2012;50(5):1201-1207.
58. Cardoso RVC, Fernandes A, Beatriz M, Oliveira PP. Development of nutraceutical formulations based on the mycelium of *Pleurotus ostreatus* and *Agaricus bisporus*. *Food Funct.* 2017;8(6):2155-2164.
59. Ghahremani-Majd H, Dashti F. Chemical composition and antioxidant properties of cultivated button mushrooms (*Agaricus bisporus*). *Hortic Environ Biotechnol.* 2015;56:376-382.
60. Ma B-J. Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in *Hericium erinaceus*. *Mycology.* 2010;1(2):92-98.
61. Heer RS, Patel NB, Mandal AKJ, Lewis F, Missouri CG. Not a fungi to be with: shiitake mushroom flagellate dermatitis. *Am J Emerg Med.* 2020;38(2):412.e1-412.e2.
62. de Mendonça CN, Chaves e Silva PM, Avelleira JCR, Nishimori FS, de Freire Cassia F. Shiitake dermatitis. *An Bras Dermatol.* 2015;90(2):276-278.
63. Hashida C, Hayashi K, Jie L, Haga S, Sakurai M, Shimizu H. [Quantities of agaritine in mushrooms (*Agaricus bisporus*) and the carcinogenicity of mushroom methanol extracts on the mouse bladder epithelium]. *Nihon Koshu Eisei Zasshi.* 1990;37(6):400-405. In Japanese.
64. Toth B, Erickson J. Cancer induction in mice by feeding of the uncooked cultivated mushroom of commerce *Agaricus bisporus*. *Cancer Res.* 1986;46(8):4007-4011.
65. Toth B. Hepatocarcinogenesis by hydrazine mycotoxins of edible mushrooms. *J Toxicol Environ Health.* 1979;5(2-3):193-202.
66. Gabriel MF, González-Delgado P, Postigo I, et al. From respiratory sensitization to food allergy: anaphylactic reaction after ingestion of mushrooms (*Agaricus bisporus*). *Med Mycol Case Rep.* 2015;8:14-16.
67. Mukai H, Watanabe T, Ando M, Katsumata N. An alternative medicine, *Agaricus blazei*, may have induced severe hepatic dysfunction in cancer patients. *Jpn J Clin Oncol.* 2006;36(12):808. 

Mushroom Quinoa Burger with Special Sauce

Serves 4


Ingredients

- 1 large portobello mushroom, gills removed, roughly chopped
- 1 cup canned black beans, rinsed
- 2 tbsp almond butter
- 3 tbsp mayonnaise, divided
- 1 tsp ground pepper
- $\frac{3}{4}$ tsp garlic powder, divided
- $\frac{1}{2}$ tsp salt
- $\frac{1}{2}$ cup cooked quinoa
- $\frac{1}{4}$ cup rolled oats
- 1 tbsp ketchup
- 1 tsp Dijon mustard
- 1 tbsp olive oil
- 4 whole-wheat hamburger buns

Directions

1. Place chopped mushroom, black beans, almond butter, 1 tablespoon mayonnaise, pepper, $\frac{1}{2}$ teaspoon garlic powder, and salt in a food processor. Pulse, stopping once or twice to scrape down the sides, until a coarse mixture forms that holds together when pressed. Transfer to a bowl and add quinoa and oats; stir well to combine. Refrigerate for 1 hour.
2. While mushroom mixture chills, whisk ketchup, mustard, and the remaining 2 tbsp mayonnaise and $\frac{1}{4}$ teaspoon garlic powder in a small bowl until smooth. Set aside.
3. Shape the chilled mushroom mixture into four patties.
4. Heat oil in a large grill pan or nonstick skillet over medium-high heat. Add the patties and cook until golden and beginning to crisp, 4 to 5 minutes. Carefully flip and cook until golden brown, 2 to 4 minutes more.
5. Serve the burgers on buns with the special sauce and add your favorite toppings, such as lettuce, spinach, pickles, tomatoes, jalapeños, and/or red or sweet onions.

Estimated Nutrition Information (one sandwich)

Calories: 494; Total Fat: 15.8g; Saturated Fat: 2.1g; Cholesterol: 3mg; Sodium: 559mg; Total Carbohydrate: 72.6g; Dietary Fiber: 13.3g; Total Sugars: 6.6g; Protein: 19.8g; Calcium: 121mg; Iron: 6mg; Potassium: 1117mg 



- my.clevelandclinic.org/health/diseases/22817-peritonsillar-abscess-quinsy. Accessed 18 Mar 2024.
24. Klug TE. Peritonsillar abscess: clinical aspects of microbiology, risk factors, and the association with parapharyngeal abscess. *Dan Med J*. 2017;64(3):B5333.
 25. Klug TE, Greve T, Hentze M. Complications of peritonsillar abscess. *Ann Clin Microbiol Antimicrob*. 2020;19(1):32.
 26. Chung JH, Lee YC, Shin SY, Eun YG. Risk factors for recurrence of peritonsillar abscess. *J Laryngol Otol*. 2014;128(12):1084–1088.
 27. Cleveland Clinic. Tonsils. 8 Jul 2022. <https://my.clevelandclinic.org/health/body/23459-tonsils>. Accessed 26 Mar 2024.
 28. National Institutes of Health. Understanding recurrent tonsillitis. 26 Feb 2019. <https://www.nih.gov/news-events/nih-research-matters/understanding-recurrent-tonsillitis>. Accessed 11 Mar 2024.
 29. Mayo Clinic Staff. Tonsillectomy. Mayo Clinic. 3 Sep 2022. <https://www.mayoclinic.org/tests-procedures/tonsillectomy/about/pac-20395141>. Accessed 26 Mar 2024.
 30. Grob GN. The rise and decline of tonsillectomy in twentieth-century America. *J Hist Med Allied Sci*. 2007;62(4):383–421.
 31. Cleveland Clinic. Tonsillectomy. 17 Oct 2022. <https://my.clevelandclinic.org/health/treatments/15605-tonsillectomy>. Accessed 25 Mar 2024.
 32. Bohr C, Shermetaro C. Tonsillectomy and adenoidectomy. In: StatPearls. StatPearls Publishing; 2024. <https://www.ncbi.nlm.nih.gov/books/NBK536942/>.
 33. Weill Cornell Medicine. What parents should know about tonsillectomy and adenoidectomy. 18 Feb 2021. <https://weillcornell.org/news/what-parents-should-know-about-tonsillectomy-and-adenoidectomy>. Accessed 26 Mar 2024.
 34. Lambert EM, You P, Kacmarynski DS, Rosenberg TL. Adenoidectomy and persistent velopharyngeal insufficiency: considerations, risk factors, and treatment. *Int J Pediatr Otorhinolaryngol*. 2021;149:110846.
 35. Hayes K. How long does it take to recover from a tonsillectomy? Very Well Health. 13 Oct 2022. <https://www.verywellhealth.com/how-long-does-it-take-to-recover-from-a-tonsillectomy-1192159>. Accessed 26 Mar 2024.
 36. Verma R, Verma RR, Verma RR. Tonsillectomy-comparative study of various techniques and changing trend. *Indian J Otolaryngol Head Neck Surg*. 2017;69(4):549–558. [NH&A](#)

Nutrition

Nutrients for DNA Damage and Repair: Spotlight on Telomere Health

By Aliza Becker, BA, MPS

Ms. Becker is the Managing Editor of *The Journal of Innovations in Cardiac Rhythm Management*. She also works as a freelance editor, a consultant for *Origin Editorial*, and a teaching assistant for the George Washington University's Master of Professional Studies in Publishing program.

Deoxyribonucleic acid (DNA) damage in the body is responsible for both normal

aging and the emergence of different health conditions.¹ Certain lifestyle choices, such as unprotected exposure to ultraviolet radiation or consuming unhealthy foods, can increase the amount of DNA damage incurred daily.² Making lifestyle changes, such as improving one's diet, may therefore have the potential to slow down aging and minimize disease onset by limiting or reversing DNA damage.

In the body, double-stranded DNA molecules coil around histone

proteins to form chromosomes, which carry genomic information between cells.³ Individual chromosomes are capped at both ends by regions of repetitive DNA sequences known as telomeres, which protect the ends of chromosomes from fraying or becoming entangled with each other.⁴ In young cells, the enzyme telomerase keeps telomeres from wearing down; as cells continue to divide, however, there is no longer enough telomerase to go around, and telomeres become

increasingly shorter until the cell can no longer divide successfully, at which point it dies.⁴ Shorter telomeres may predispose individuals to a variety of diseases, including cancer, and a greater risk of mortality.⁵ Telomere shortening is a natural part of the aging process, and inflammation may exacerbate the rate of telomere attrition, which leads to telomere dysfunction-mediated cellular senescence to further accelerate the aging process;⁶ it has also been postulated that telomere shortening may promote inflammation,⁷ leading to a potential feedback loop between the two phenomena.

Research suggests that diet can influence telomere length, although different macro- and micronutrients may have variable effects depending in part on their pro- or anti-inflammatory potential. It has been reported that dietary fiber is protective against high levels of C-reactive protein (CRP), a marker of acute inflammation,⁸ and more fiber appears to be good for telomere health.⁹ Cereal fiber, relative to vegetable and fruit fiber, has shown a more consistent association with lower inflammation,¹⁰ and other research has concluded that cereal dietary fiber intake in particular is positively linked to leukocyte telomere length.¹¹

Meanwhile, different types of fat seem to impact telomere length in different ways. Saturated fat and telomere length are negatively correlated.^{12,13} Monounsaturated fatty acids collectively seem to have either a negative¹² or no association¹³ with lymphocyte telomere length. Meanwhile, the reported effects of polyunsaturated fatty acids, although potentially positive overall,¹² are more complex: while the intake of

linoleic acid (found in vegetable oils, nuts, seeds, meats, and eggs) was inversely associated with leukocyte telomere length,¹¹ that of another polyunsaturated fatty acid, arachidonic acid, was positively correlated with leukocyte telomere length.¹² In another study, blood levels of marine omega-3 fatty acids, another kind of polyunsaturated fatty acid, were also found to be inversely associated with the rate of leukocyte telomere shortening over a period of five years—that is, higher levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EHA) helped to slow down leukocyte telomere shortening over time.¹⁴ It is important to note, however, that this study was conducted in a population of 608 outpatients with stable coronary artery disease,¹⁴ and other research has suggested that the relationship between telomere shortening and macronutrients can be complicated by disease. Using data from the United States (US) National Health and Nutrition Examination Survey (NHANES), investigators in one study found that telomere length was positively correlated with high-density lipoprotein (HDL) cholesterol levels in individuals without diabetes, hypertension, coronary atherosclerotic heart disease, or hyperuricemia, yet the same relationship could not be identified in individuals with these conditions, which the authors attributed to the presence of HDL cholesterol dysfunction in these diseases.¹⁵

Other conditions, such as persistent high cholesterol (dyslipidemia), may also correlate with accelerated shortening of telomere length over time;¹⁶ indeed, it is suggested that high serum lipid concentrations

may be associated with systemic inflammation and atherosclerosis, which could lead to oxidative stress, resulting in telomere shortening and dysfunction.^{17,18} In this vein, some research has suggested that antioxidant intake may positively influence telomere length. One study of Spanish children and adolescents found a positive correlation between the general dietary total antioxidant capacity and telomere length after adjustment for age and energy intake.¹⁹ Other studies have also linked specific antioxidants to longer telomeres, including minerals, such as zinc and selenium;^{20,21} vitamins C and E;^{22,23} and carotenoids, such as lutein, zeaxanthin, and alpha- and beta-carotene.^{24,25} However, one study determined that gamma-tocopherol (a form of vitamin E), found in nuts, vegetable oils, and seeds, but not alpha-tocopherol (another form of vitamin E), negatively impacted telomere length, with adults in the 75th percentile of gamma-tocopherol showing 2.8 to 3.4 years of greater cellular aging than those at the 25th percentile, depending on the covariates in the model.²⁶ The choice of antioxidant may therefore matter with regard to telomeric effects.


Consumption of sugar-sweetened beverages (SSBs) like soda and sports drinks have also been linked to shortened telomeres,²⁷ while the intake of 100-percent fruit juice may help to ensure longer telomeres.²⁸ Although it was unclear what the SSBs in question were sweetened with, other research contends that fructose, found in fruit juice, may lead to lower blood glucose and insulin concentrations²⁹ than either glucose or sucrose. The consumption of 100-percent fruit juice may also impart

beneficial effects of phytochemicals and micronutrients (e.g., antioxidant vitamins) to balance out the negative effect of its sugar content.³⁰ However, other research contends that greater intakes of both total and added fructose are significantly associated with shorter relative telomere length,³¹ and the intake of 100-percent fruit juice in the aforementioned study²⁸ led to only a marginal association with longer telomeres. Telomere shortening has also been linked to elevated fasting glucose, hemoglobin A1c (HbA1c), and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) values,^{32,33} which can be indicators of progression toward diabetes, and patients with diabetes have shorter telomeres compared to healthy individuals.³⁴ Insulin resistance itself, the hallmark of diabetes, induces inflammation,³⁵ which has been linked to telomere shortening. As such, minimizing the consumption of all sugars may help to prevent accelerated telomere shortening.

Research on the link between protein intake and telomere length is limited; however, greater protein intake supports a lower-calorie diet,³⁶ helping to minimize inflammation.³⁷ Importantly, though, the source of the protein might matter; for example, the consumption of red meat²⁷ and particularly processed meats^{27,38,39} has been inversely linked to telomere shortening. Although the trend may be linked to greater concentrations of certain nutrients, such as saturated fat, processed meat also contains high concentrations of advanced glycation end-products and nitrosamines that may promote inflammation and oxidative stress.^{38,40} Moreover, considering for a moment other types of DNA damage, an

FOR A HEALTHY FRUIT SNACK, WHAT WOULD YOU CHOOSE?

Dried fruit has the best nutrition profile of all commercially available fruit snacks, with the highest nutrient density and fiber content and lowest added sugar content, according to a study from the University of Massachusetts Amherst. Canned fruit with juice and fruit puree also met current recommendations for nutrient dense snacks. Fruit-flavored snacks (e.g., gummies) had the highest added sugar content and lowest nutrient density and fiber content. Dried flavored fruit and canned fruit packed in something other than juice also had low nutrient density and high added sugar content.

Source: ScienceDaily. For a healthy fruit snack, what would you choose? 5 Mar 2024. <https://www.sciencedaily.com/releases/2024/03/240305165908.htm>. Accessed 26 Mar 2024. 



analysis of tumors from patients with colorectal cancer revealed a specific “alkylating” pattern of DNA damage attributed to the production of certain compounds in the body following the consumption of red and processed meat,⁴¹ and the intake of heterocyclic amines, a kind of carcinogen formed when meat, poultry, or fish is cooked at high temperatures, has also been suggested to result in DNA alkylation through their bioactivation upon consumption into reactive species.^{42,43} As such, it is recommended to limit intake of animal products, especially processed meats, to avoid DNA damage, including telomere shortening.

Ultra-processed food, which typically contains greater amounts of saturated and trans fats, sugar, and salt—all of which trigger inflammation⁴⁴—has been linked to shorter telomeres. A population of elderly Spanish individuals with the greatest consumption of ultra-processed food demonstrated almost twice the odds of having short telomeres, compared to those with the lowest consumption.⁴⁵ Beneficial nutrients

are also typically stripped away during the industrial processes used to produce ultra-processed foods, and research suggests that deficiencies in folate, niacin, iron, and zinc as well as vitamins B12, B6, C, and E can mimic the DNA-damaging effects of radiation by causing single- and double-strand breaks, oxidative lesions, or both.⁴⁶

Conversely, the Mediterranean diet in particular might support longer leukocyte telomeres,^{47,48} one study of individuals at high risk for cardiovascular disease observed longer telomeres at baseline in participants with a more anti-inflammatory diet (lowest Dietary Inflammatory Index score) and, following a five-year intervention with the Mediterranean diet, longitudinal analyses suggested that a diet with greater anti-inflammatory potential could significantly slow down the rate of telomere shortening.⁴⁹ In other research comparing two major dietary patterns—“the prudent dietary pattern,” which was characterized by a high intake of whole grains, fish and seafood, legumes, vegetables, and seaweed, and the “Western dietary

pattern,” which was characterized by a high intake of refined grain, red meat or processed meat, and sweetened carbonated beverages—the “prudent dietary pattern” was found to be positively associated with leukocyte telomere length, while an inverse trend was observed for the association between the “Western dietary pattern” and leukocyte telomere length.²⁷

Finally, one study contended that the very act of cooking foods—including vegetables—at high temperatures might result in DNA mutations, abasic sites, or double-strand breaks by way of metabolic salvage; its authors noted distinct differences in the level of damage according to time and type of cooking, with roasting (220°C) causing more damage to food than boiling (100°C).⁴³ However, the authors of this study stress that more research is necessary.

Editor’s notes. Although telomeres exist in all cells, leukocyte telomere length is the measure most commonly used in telomere length research.

Please discuss any health concerns, including those regarding your diet, with your primary care physician.

SOURCES

- Guo J, Huang X, Dou L, et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. *Sig Transduct Target Ther*. 2022;7:391.
- Barsouk A. How summer and diet damage your DNA, and what you can do. *The Conversation*. 16 Jul 2018. <https://theconversation.com/how-summer-and-diet-damage-your-dna-and-what-you-can-do-99269>. Accessed 16 Mar 2024.
- NIH National Human Genome Research Institute. Chromosome. <https://www.genome.gov/genetics-glossary/Chromosome>. Accessed 9 Dec 2023.
- NIH National Human Genome Research Institute. Telomere. <https://www.genome.gov/genetics-glossary/Telomere>. Accessed 9 Dec 2023.
- Schneider CV, Schneider KM, Teumer A, et al. Association of telomere length with risk of disease and mortality. *JAMA Intern Med*. 2022;182(3):291–300.
- Liu S, Nong W, Ji L, et al. The regulatory feedback of inflammatory signaling and telomere/telomerase complex dysfunction in chronic inflammatory diseases. *Exp Gerontol*. 2023;174:112132.
- Niveta JPS, Kumar MA, Parvathi VD. Telomere attrition and inflammation: the chicken and the egg story. *Egypt J Med Hum Genet*. 2022;23:131.
- Ma Y, Griffith JA, Chasan-Taber L, et al. Association between dietary fiber and serum C-reactive protein. *Am J Clin Nutr*. 2006;83(4):760–766.
- Tucker LA. Dietary fiber and telomere length in 4674 US adults: an NHANES study of biological aging. *Nutrients*. 2018;10(4):400.
- Shivakoti R, Biggs ML, Djoussé L, et al. Intake and sources of dietary fiber, inflammation, and cardiovascular disease in older US adults. *JAMA Netw Open*. 2022;5(3):e225012.
- Cassidy A, De Vivo I, Liu Y, et al. Associations between diet, lifestyle factors, and telomere length in women. *Am J Clin Nutr*. 2010;91(5):1273–1280.
- Dhillon VS, Deo P, Chua A, Thomas P, Fenech M. Telomere length in healthy adults is positively associated with polyunsaturated fatty acids, including arachidonic acid, and negatively with saturated fatty acids. *J Gerontol A Biol Sci Med Sci*. 2021;76(1):3–6.
- Song Y, You N-CY, Kang MK, et al. Intake of small-to-medium-chain saturated fatty acids is associated with peripheral leukocyte telomere length in postmenopausal women. *J Nutr*. 2013;143(6):907–914.
- Farzaneh-Far R, Lin J, Epel ES, et al. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. *JAMA*. 2010;303(3):250–257.
- Chen Y-F, Zhou K-W, Yang G-Z, Chen C. Association between lipoproteins and telomere length in US adults: data from the NHANES 1999–2002. *Lipids Health Dis*. 2019;18:80.
- Liu X, Ma T, Yang C, Li J, et al. Persistent dyslipidemia increases the longitudinal changes in telomere length. *Lipids Health Dis*. 2023;22:173.
- Karimi B, Yunesian M, Nabizadeh R, Mehdipour P. Serum level of total lipids and telomere length in the male population: a cross-sectional study. *Am J Mens Health*. 2019;13(2):1557988319842973.
- Barnes RP, Fouquerel E, Opresko PL. The impact of oxidative DNA damage and stress on telomere homeostasis. *Mech Ageing Dev*. 2019;177:37–45.
- García-Calzón S, Moleres A, Martínez-González MA. Dietary total antioxidant capacity is associated with leukocyte telomere length in a children and adolescent population. *Clin Nutr*. 2015;34(4):694–699.
- Shu Y, Wu M, Yang S, et al. Association of dietary selenium intake with telomere length in middle-aged and older adults. *Clin Nutr*. 2020;39(10):3086–3091.
- Shi H, Li X, Yu H, et al. Potential effect of dietary zinc intake on telomere length: a cross-sectional study of US adults. *Front Nutr*. 2022;9:993425.
- Xu Q, Parks CG, DeRoo LA, et al. Multivitamin use and telomere length in women. *Am J Clin Nutr*. 2009;89(6):1857–1863.
- Cai Y, Zhong Y, Zhang H, et al. Association between dietary vitamin C and telomere length: a cross-sectional study. *Front Nutr*. 2023;10:1025936.
- Sen A, Marsche G, Freudenberger P, et al. Association between higher plasma lutein, zeaxanthin, and vitamin C concentrations and longer telomere length: results of the Austrian Stroke Prevention Study. *J Am Geriatr Soc*. 2014;62(2):222–229.
- Min K-B, Min J-Y. Association between leukocyte telomere length and serum carotenoid in US adults. *Eur J Nutr*. 2017;56(3):1045–1052.
- Tucker LA. Alpha- and gamma-tocopherol and telomere length in 5768 US men and women: a NHANES study. *Nutrients*. 2017;9(6):601.
- Lee J-Y, Jun N-R, Yoon D, et al. Association between dietary patterns in the remote past and telomere length. *Eur J Clin Nutr*. 2015;69(9):1048–1052.
- Leung CW, Laraia BA, Needham BL, et al.

- Soda and cell aging: associations between sugar-sweetened beverage consumption and leukocyte telomere length in healthy adults from the National Health and Nutrition Examination Surveys. *Am J Public Health*. 2014;104(12):2425–2431.
29. Evans RA, Frese M, Romer J, et al. Fructose replacement of glucose or sucrose in food or beverages lowers postprandial glucose and insulin without raising triglycerides: a systematic review and meta-analysis. *Am J Clin Nutr*. 2017;106(2):506–518.
 30. Leung CW, Laraia BA, Needham BL, et al. Soda and cell aging: associations between sugar-sweetened beverage consumption and leukocyte telomere length in healthy adults from the National Health and Nutrition Examination Surveys. *Am J Public Health*. 2014;104(12):2425–2431.
 31. Messerlian N, Zgheib N, Al Zahraa Chokor F, et al. Fructose intake and its association with relative telomere length: an exploratory study among healthy Lebanese adults. *Front Nutr*. 2023;10:1270124.
 32. Grunnet LG, Pilgaard K, Alibegovic A, et al. Leukocyte telomere length is associated with elevated plasma glucose and HbA1c in young healthy men independent of birth weight. *Sci Rep*. 2019;9:7639.
 33. Gardner JP, Li S, Srinivasan SR, et al. Rise in insulin resistance is associated with escalated telomere attrition. *Circulation*. 2005;111(17):2171–2177.
 34. Wang J, Dong X, Cao L, et al. Association between telomere length and diabetes mellitus: a meta-analysis. *J Int Med Res*. 2016;44(6):1156–1173.
 35. Shimobayashi M, Albert V, Woelnerhanssen B, et al. Insulin resistance causes inflammation in adipose tissue. *J Clin Invest*. 2018;128(4):1538–1550.
 36. Weigle DS, Breen PA, Matthys CC, et al. A high-protein diet induces sustained reductions in appetite, ad libitum caloric intake, and body weight despite compensatory changes in diurnal plasma leptin and ghrelin concentrations. *Am J Clin Nutr*. 2005;82(1):41–48.
 37. Kökten T, Hansmann F, Ndiaye NC, et al. Calorie restriction as a new treatment of inflammatory diseases. *Adv Nutr*. 2021;12(4):1558–1570.
 38. Fretts AM, Howard BV, Siscovick DS, et al. Processed meat, but not unprocessed red meat, is inversely associated with leukocyte telomere length in the Strong Heart Family Study. *J Nutr*. 2016;146(10):2013–2018.
 39. Nettleton JA, Diez-Roux A, Jenny NS, Fitzpatrick AL, Jacobs Jr. DR. Dietary patterns, food groups, and telomere length in the Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Clin Nutr*. 2008;88(5):1405–1412.
 40. Galiè S, Canudas S, Muralidharan J, et al. Impact of nutrition on telomere health: systematic review of observational cohort studies and randomized clinical trials. *Adv Nutr*. 2020; 11(3):576–601.
 41. Gurjao C, Zhong R, Haruki K, et al. Discovery and features of an alkylating signature in colorectal cancer. *Cancer Discov*. 2021;11(10):2446–2455.
 42. Martins de Carvalho A, Carioca AAF, Fisberg RM, et al. Joint association of fruit, vegetable, and heterocyclic amine intake with DNA damage levels in a general population. *Nutrition*. 2016;32(2):260–264.
 43. Jun YW, Kant MV, Coskun E, et al. Possible genetic risks from heat-damaged DNA in food. *ACS Cent Sci*. 2023;9(6):1170–1179.
 44. Christ A, Lauterbach M, Latz E. Western diet and the immune system: an inflammatory connection. *Immunity*. 2019;51(5):794–811.
 45. Alonso-Pedrero L, Ojeda-Rodríguez A, Martínez-González MA, et al. Ultra-processed food consumption and the risk of short telomeres in an elderly population of the Seguimiento Universidad de Navarra (SUN) Project. *Am J Clin Nutr*. 2020;111(6):1259–1266.
 46. Ames BN. Micronutrient deficiencies. A major cause of DNA damage. *Ann N Y Acad Sci*. 1999;889:87–106.
 47. Boccardi V, Esposito A, Rizzo MR, et al. Mediterranean diet, telomere maintenance and health status among elderly. *PLoS One*. 2013;8(4):e62781.
 48. Crous-Bou M, Fung TT, Prescott J, et al. Mediterranean diet and telomere length in Nurses' Health Study: population-based cohort study. *BMJ*. 2014;349:g6674.
 49. García-Calzón S, Zalba G, Ruiz-Canela M. Dietary inflammatory index and telomere length in subjects with a high cardiovascular disease risk from the PREDIMED-NAVARRA study: cross-sectional and longitudinal analyses over 5 y. *Am J Clin Nutr*. 2015;102(4):897–904. **NHR**

HOW EATING DISORDERS CAN DAMAGE THE HEART

Eating disorders can lead to cardiovascular complications, such as bradycardia, congestive heart failure, and sudden cardiac death. The way eating disorders affect heart health can vary depending on the specific disorder. For example, weight loss and malnutrition in anorexia—which is characterized by body image distortion and restricted food intake and may involve excessive exercise and binge eating—can cause heart muscles to atrophy, which can then lead to bradycardia. Bulimia—which is characterized by body image distortion, binge eating, and purging behaviors—can cause electrolyte imbalances due to excessive vomiting and laxative use, thereby increasing the risk of abnormal heart rhythms. Postural orthostatic tachycardia syndrome (POTS) might also occur in individuals with eating disorders. Symptoms of POTS include rapid heartbeat, heart palpitations, dizziness, and lightheadedness. Eating disorder-related cardiovascular symptoms can include lightheadedness, chest pain, lack of energy, shortness of breath, and frequent nose bleeds. Treating the underlying eating disorder can help resolve cardiovascular complications.

Source: Williamson L. How eating disorders can damage the heart. American Heart Association. 26 Feb 2024. <https://www.heart.org/en/news/2024/02/26/how-eating-disorders-can-damage-the-heart>. Accessed 29 Mar 2024. **NHR**

